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VENTRAL TEGMENTAL AREA NEURONAL RESPONSES TO METHYLPHENIDATE
CORRELATED TO BEHAVIORAL RESPONSES OF ADOLESCENT AND
ADULT RATS

Zachary Ryan Jones, B.S.
Supervisory Professor: Nachum Dafny, Ph.D.
Abstract
Methylphenidate (MPD) is a psychostimulant used in the treat treatment of attention
deficit hyperactivity disorder and more recently is being used as a cognitive enhancement and
recreational drug. Its therapeutic effects are not fully understood, nor are the long term effects of
the drug on brain development. The ventral tegmental area (VTA) is a site of psychostimulant
action thought to be involved in behavioral sensitization. The aim of the this study was to first
determine if there are differences in neuronal responses between individuals, with respect to
neuronal firing patterns in the ventral tegmental area (VTA), and whether these differences are
responsible for the conflicting reports on behavioral responses with chronic MPD exposure.
Additionally, we wanted to determine if the same dose of MPD can cause both behavioral
sensitization and behavioral tolerance and to examine if there are intrinsic differences in the VTA
neuronal activity between the behaviorally sensitized and tolerant animals. One hundred and
thirteen adolescent animals and 51 adult rats were divided into 4 groups: saline, 0.6, 2.5, and 10.0
mg/kg MPD and had their neuronal and behavioral activity recorded concomitantly following one
of the chosen MPD doses. In order to determine if there are neuronal differences between these
two groups the VTA neuronal activity was evaluated based on the animals’ behavioral response
to chronic MPD exposure. In conclusion, acute MPD exposure elicits dose related increases in
behavioral activity and following chronic MPD exposure, it was shown that the same repetitive
MPD dose can elicit either behavioral sensitization or tolerance in both adolescent and adult
animals. Differences were observed between the adolescent and adult for both the neuronal and
behavioral data for each dose of MPD tested.
vi

Table of contents
Contents

Page No.

i.

Signature Page

i

ii.

Title Page

ii

iii.

Dedications

iii

iv.

Acknowledgements

iv

v.

Abstract

v

1. Introduction

1

2. Materials and Methods

12

2.1 Animals

12

2.2 Surgeries

12

2.3 Drugs

13

2.4 Experimental Protocol

14

2.5 Behavioral Recording System

17

2.6 Electrophysiological Apparatus

17

2.7 Data Analysis

18

2.7.1 Behavioral Analysis

18

2.7.2 Spike Sorting

18

2.7.3 Electrophysiological Data Evaluation

19

2.7.4 Histological Verification

21

3. Results

24

3.1 Adolescent

24

3.2 Behavioral Results Adolescent

24

3.2.1 Adolescent 0.6 mg/kg MPD

26

3.2.2 Adolescent 2.5 mg/kg MPD

28

vii

3.3.3 Adolescent 10.0 mg/kg MPD

30

3.3 Adults

32

3.4 Behavioral Results Adult

32

3.4.1

Adult 0.6 mg/kg MPD

32

3.4.2

Adult 2.5 mg/kg MPD

35

3.4.3

Adult 10.0 mg/kg MPD

37

3.5 Comparison between Adolescent and Adult Behavior

39

3.6 Neuronal Activity Adolescent

39

3.6.1

Adolescent VTA Neuronal (0.06 mg/kg)

3.6.2

Adolescent VTA neuronal based on behavior

41

(0.6 mg/kg)

41

3.6.3

Adolescent VTA Neuronal (2.5 mg/kg)

44

3.6.4

Adolescent VTA neuronal based on behavior
(2.5 mg/kg)

44

3.6.5

Adolescent VTA Neuronal (10.0 mg/kg)

48

3.6.6

Adolescent VTA neuronal based on behavior
(10.0 mg/kg)

48

3.7 Neuronal Activity Adult

52

3.7.1

Adult VTA Neuronal (0.06 mg/kg)

52

3.7.2

Adult VTA neuronal based on behavior (0.6 mg/kg)

53

3.7.3

Adult VTA Neuronal (2.5 mg/kg)

58

3.7.4

Adult VTA neuronal based on behavior (2.5 mg/kg)

58

3.7.5

Adult VTA Neuronal (10.0 mg/kg)

63

3.7.6

Adult VTA neuronal based on behavior (10.0 mg/kg)

63

viii

3.8 Statistical Comparisons
3.8.1

68

Adolescent behavioral tolerance compared to
sensitized (0.06 mg/kg)

3.8.2

Adolescent behavioral tolerance compared to
sensitized (0.06 mg/kg)

3.8.3

68

68

Adolescent behavioral tolerance compared to
sensitized (0.06 mg/kg)

68

3.8.4

Adult behavioral tolerance to sensitized (0.06 mg/kg)

69

3.8.5

Adult behavioral tolerance to sensitized (2.5 mg/kg)

69

3.8.6

Adult behavioral tolerance to sensitized (10.0 mg/kg)

70

3.8.7

Comparison between Adolescent and Adult Animals

70

4. Discussion

71

5. Bibliography

80

6. Vita

87

ix

List of Illustrations
Figure no.

Title of Figure

Page No.

1.

Illustration of VTA in human brain

10

2.

Histological Verification of adolescent electrode

22

3.

Histological Verification of adult electrode

23

4.

Baseline Behavioral response (saline)

25

5.

Adolescent Behavior (0.6 mg/kg)

27

6.

Adolescent Behavior (2.5 mg/kg)

29

7.

Adolescent Behavior (10.0 mg/kg)

31

8Aa.

Adult Behavior All (0.6 mg/kg)

34

8Ab.

Adult Behavior Sensitized (0.6 mg/kg)

34

8Ac.

Adult Behavior Tolerant (0.6 mg/kg)

34

9Bd.

Adult Behavior All (2.5 mg/kg)

36

9Be.

Adult Behavior Sensitized (2.5 mg/kg)

36

9Bf.

Adult Behavior Tolerant (2.5 mg/kg)

36

10Cg.

Adult Behavior All (10.0 mg/kg)

38

10Ch.

Adult Behavior Sensitized (10.0 mg/kg)

38

10Ci.

Adult Behavior Tolerant (10.0 mg/kg)

38

11.

Baseline Neuronal Response (saline)

40

12.

Representative 2.5 mg/kg firing histogram

46

13.

Representative 10.0 mg/kg firing histogram

50

14.

Adult Firing Histogram (0.6 mg/kg)

57

15.

Adult Firing Histogram (2.5 mg/kg)

62

16.

Adult Neurophysiological Sens/Tol (10.0 mg/kg)

67

x

List of Tables
Table No.

Title of the Table

Page No.

1.

Experimental Protocol

16

2A.

VTA neuronal response patterns 0.6 mg/kg

43

2B.

Adolescent VTA neuronal - Behaviorally sensitized 0.6 mg/kg

43

2C.

Adolescent VTA neuronal - Behaviorally tolerant 0.6 mg/kg

43

3A.

Adolescent VTA neuronal response patterns 2.5 mg/kg

47

3B.

Adolescent VTA neuronal - Behaviorally sensitized 2.5 mg/kg

47

3C.

Adolescent VTA neuronal - Behaviorally tolerant 2.5 mg/kg

47

4A.

Adolescent VTA neuronal response patterns 10.0 mg/kg

51

4B.

Adolescent VTA neuronal - Behaviorally sensitized 10.0 mg/kg 51

4C.

Adolescent VTA neuronal - Behaviorally tolerant 10.0 mg/kg

51

5.

Adult VTA neuronal response patterns 0.6 mg/kg

55

6.

Adult VTA neuronal responding units 0.6 mg/kg

56

7.

Adult VTA neuronal response patterns 2.5 mg/kg

60

8.

Adult VTA neuronal responding units 2.5 mg/kg

61

9.

Adult VTA neuronal response patterns 10.0 mg/kg

65

10.

Adult VTA neuronal responding units 10.0 mg/kg

66

xi

1 Introduction
The History of MPD and its Uses
Methylphenidate (MPD) is a psychostimulant most commonly used in the treatment of
attention deficit hyperactivity disorder (ADHD) in adolescents and adults (Challman and Lipsky,
2000; Garland 1998; Lee et al., 2012; Solanto 1998). Methylphenidate (Ritalin) was first synthesized
in 1944 (U.S. Pharmacist, 2002) in 1954 its testing on humans had begun (U.S. Pharmacist, 2002).
During the year 1957, Ciba Pharmaceutical Company began marketing MPD for the treatment of
narcolepsy, chronic fatigue, psychosis, and depression (U.S. Pharmacist, 2002). In 1960, MPD was
marketed as Ritonic, and was used to treat and improve the patients’ mood and to help maintain
cognitive vitality (U.S. Pharmacist, 2002). During the 1970’s and 80’s, MPD was starting to be used
for the treatment of ADHD. The symptoms of ADHD, as described in the Diagnostic and Statistical
Manual for Mental Disorders (DSM IV), are as follows: inattention, hyperactivity, and impulsivity
for a period of at least six months that causes impairment both at home and at school or work (DSM
IV 1994 4th Ed.). This disorder can cause children to have trouble concentrating and misbehave in
school and can also create social misconduct in the affected individuals (Newcorn, 2000). From the
years 1990-1999, there was a 500% increase in the use of MPD in the United States (U.S.
Pharmacist, 2002) and the daily doses administered to patients had increased from 75 million in 1990
to 360 million in 1998 (Woodworth, 2000). It was estimated that the United States consumes 85% of
the world’s supply of MPD (Woodworth, 2000). In addition, with the 2000 US census population of
over 281 million individuals, it was approximated that one out of five hundred randomly chosen
people are currently prescribed with Ritalin (Woodworth, 2000). Today, MPD is still the
pharmacotherapy of choice and gold standard in the treatment of ADHD.
However, due to the overabundance of adolescents being prescribed MPD there has become
a high risk of nonmedical use and abuse by patients and their peers and family members. According
to the National Survey on Drug Use and Health, nonmedical use of a medication is defined as;
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“The use of prescription type psychotherapeutic drugs not prescribed for the respondent by a
physician or the use of a drug only for the experience or the feeling it caused”

(www.oas.samhsa.gov).

Drug abuse is defined as
“The use of a drug for a nontherapeutic effect, and habitual use of drugs to alter one’s mood,
emotion, or state of consciousness”

(www.oas.samhsa.gov).
Recently, the recreational use of MPD by adolescent and young adults has risen dramatically
(Arria and Wish, 2006; Imbert et al., 2013) and there have been a large number of studies supporting
the assertion that MPD is abused at a high rate by adolescents and adults (McCabe et al., 2007; Teter
et al., 2006; Wilens et al., 2005). One such study focusing on undergraduate college students, found
that over 30% of students that were tested had taken non-prescribed MPD either to get high or to aid
in their studying (Teter et al., 2006; Wilens et al., 2005). In a 2006 study of college students,
McCabe et al. found that 16% of those tested had abused stimulants for the cognitive enhancement
effect, with 96% of them preferring Ritalin/MPD as their drug of choice (McCabe et al., 2007).
Likewise, a study involving 700 participants aged 12 to 44 found that 22.9% had given some of their
prescription to someone else, 26.9% had borrowed someone else’s, and 39.4% were willing to share
their medication with family members (Goldsworthy et al., 2008). This study also reported that
20.8% of subjects between the ages of 18 and 25 have borrowed prescription medication to relax or
feel good compared to only 10% of those aged 36 to 44 , which indicates that young people are more
likely to use and abuse MPD. Additionally, this study also reported that 34.1% of adolescents said
they were more likely to use Ritalin/MPD if it came from someone they were close to or who was
familiar with the drug (Goldsworthy et al., 2008). These statistics on nonmedical MPD use highlights
the importance of studies which examine the short and long term effects of MPD exposure to further
expand the long term effects of the drug on the brain and overall health.
The behavioral effects following short term MPD exposure have been well documented
(Brands et al., 1998). However, the data for more long term MPD exposures have not been fully
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explored and are still not completely understood. Some of the short term behavioral effects which
occur with low doses of MPD are wakefulness, heightened alertness, appetite suppression, and
several negative effects such as impairment of voluntary movement, headache, and vomiting (Brands
et al., 1998). In addition, with higher doses of MPD, there are many short term behavioral effects
which include agitation, exhilaration, muscle twitching, excitation, dilation of pupils, increased
blood pressure, other sympathetic responses, confusion, hallucinations, increased pulse rate,
delirium, paranoia, repetition of movements and meaningless tasks and even seizures followed by
coma can occur (Borcherding et al., 1990; Masand and Tesar, 1996). There have been a few studies
on the long term effects of low and high dose MPD exposure. One such study with the use of
positron emission tomography (PET) scans discovered that the extended use of MPD can constrict
blood flow to the brain which may causes an increase in blood pressure (Wang et al., 1994). Among
a number of other behavioral studies examining the long term effects of MPD use have come up with
conflicting results (Lambert, 1999; Piazza et al., 1989; Robinson and Berridge, 1993; Wilens et al.,
2005). One such study reported that MPD treatment provided protection to adolescents from later
drug dependence (Wilens et al., 2005), while another study found the opposite to be true, namely that
MPD use created a certain susceptibility to drug use later in life (Lambert, 1999; Piazza et al., 1989;
Robinson and Berridge, 1993). Additionally, another longitudinal study reported no direct
correlation between adolescent or youth stimulant use and drug use later on in the individual’s life
(Barkley et al., 2003). With the amount of contradictory information among the literature, we believe
that recording both behavior and neuronal activity concomitantly will give us a better idea as to why
there are so many differing views. We want to first determine if there are differences between the
adolescent response to MPD and the adult response to MPD. Following this, further research can be
done to test the same animal throughout adolescence into adulthood to examine whether the
longitudinal response to MPD has changed.
Due to the increased prescription of MPD to young children who do not have fully
developed brains, it is important to understand the way this drug affects adolescents compared to
3

adults. The current research will help show how a stimulant like MPD affects a developing brain in
young subjects, versus how it affects a brain that is fully developed. Many changes are still occurring
in young developing brains with synaptic outgrowth and pruning which help to shape the adult brain.
What effects that drugs like MPD have on the adolescent brain is still largely unknown. MPD has a
chemical structure similar to amphetamine and methamphetamine and has neuropharmalogical
characteristics to cocaine (Kallman and Isaac, 1975; Patrick and Markowitz, 1997; Teo et al., 2003;
Volkow, 2001). Therefore, due to its close similarities to these drugs of abuse, MPD poses the risk as
a drug of addiction. MPD has a similar mechanism of action to cocaine in that it acts as an indirect
agonist of dopamine (DA) by binding with high affinity to the dopamine transporter (DAT), blocking
the DA reuptake back into the presynaptic terminal. This in turn causes increased levels of
extracellular DA in the synaptic cleft giving the postsynaptic longer exposure to the released DA
increasing the rate of postsynaptic binding. MPD is absorbed and metabolized via de-esterification to
ritalinic acid and is usually found in the urine within 48 hours of use (Faraj et al., 1974; Wang et al.,
1997; Wargin et al.,1983). Because the psychostimulant is concentrated in the catecholaminergic
systems, and has free flow across the blood brain barrier, the subsequent concentration of MPD in
the brain exceeds the plasma levels. In addition, MPD also has a rapid uptake in the brain like
cocaine, except MPD has a much lower rate of clearance (Morse et al., 1995). This may explain why
i.v. or intranasal administration of MPD has higher mortality rates than both cocaine and
amphetamines for higher doses (Gatley et al., 1999; Volkow et al., 1995, 1996, 1999). Most users
who recreationally use MPD to get high are not aware of the dangers associated with their actions,
thus there is a great danger in the misuse of the drug.
The dosage and route of administration of MPD plays a large role in the experience of the
user, due to the fact that the behavioral responses and the neurochemical reactions to the drug are
dependent upon both the length of time it takes for the drug to reach its peak level in the periphery
and how long the drug is in the system (Kuczenski and Segal., 2002). When MPD is administered
orally, which is the normal route for ADHD patients; it is absorbed through the intestinal tract having
4

a half-life around 1 hour and shows peaks in the blood approximately 60-90 minutes after ingestion
(Garland 1998; Gerasmiov et al., 2000; Kuczenski and Segal 2002; Solanto 1998, 2000; Stewart &
Badiani 1993). Following intravenous (i.v) injection or intraperitoneal (i.p.) administration, peak
levels of MPD in the periphery are reached at approximately 8-20 minutes and 15-28 minutes,
respectively (Gerasmiov et al., 2000; Kuczenski and Segal 2002; Stewart & Badiani 1993). The
ability to reach peak levels rapidly (8-30 minutes) is one of the main factors responsible for both the
euphoric/pleasurable responses and the adverse effects, such as a sensitization response.
ADHD in Adolescents and Adults
It has been estimated that worldwide, about 5% of children and 4% of adults are affected
with ADHD and in the U.S. around 8.7% of the children tested meet the criteria for ADHD
(Froehlich et al., 2007; Polancyzk and Rohde, 2007; Wilens et al., 2005). Therefore, it is not
uncommon for MPD to be prescribed to children as early as elementary school, a time when the
brain is still going through development (Lakhan and Kirchgessner, 2012). In fact, the percentage of
children between the ages of 4–17 years who have been diagnosed with ADHD has increased from
7.8% in 2003 to 9.5% in 2007, representing a 21.8% increase in just 4 years (Center for Disease
Control and Prevention, 2010). Because so many children are being prescribed psychostimulants at
young ages, more research needs to be carried out to better understand the way that these drugs
affect young brains. The current literature on adolescent methylphenidate studies is lacking, and it
remains unclear how exactly drugs like methylphenidate affect young developing brains and whether
that is different than its effects in adult brains. Between 5 and 15 years of age, the human brain goes
through a process of over production of synaptic connections and receptors followed by their pruning
and competitive elimination, which may serve as a factor in the development of behavior disorders
(Andersen and Teicher, 2000; Brenhouse and Andersen, 2011; Huttenlocher, 1974; Rakic et al.,
1986).
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Behavioral and chemical studies have reported that MPD affects the young differently than
adults (Brandon et al., 2003; Canese et al., 2010; Dafny and Yang, 2006; Yang et al., 2011).
However, there have not been any studies done recording both neuronal and behavioral recordings
concomitantly. MPD exposure has been shown to produce an age dose dependent increase in
extracellular levels of DA and in norepinephrine (NE) levels (Kuczenski and Segal, 2001). Walker et
al. (2010) reported that the extracellular DA levels in adolescents treated with MPD are higher than
those in adults who have been treated with MPD. In anesthetized animals, MPD was reported to
affect neuronal functions differently in the young compared to adults (Gronier et al., 2010). A
functional MRI study has reported drastically different responses to MPD between adolescent and
adults (Canese et al., 2009). Thus it is possible to assume that MPD efficacy will be different in
young populations when compared to adults. Therefore it is important to study the role of MPD in
adolescents as well as adults to examine if differences exist between the two when treated with
MPD.
Behavioral Sensitization and Tolerance Following MPD Administration
Chronic exposure to psychostimulants such as MPD can result in the initiation and alteration
of biochemical, molecular, and morphological configuration as well as behavioral changes which can
lead to plasticity in the CNS (Chao and Nestler, 2004; Dafny and Yang, 2006; Dietz et al., 2009;
Kim et al., 2009; Nestler 2004; Robison and Nestler, 2011). MPD has been shown to cause different
behavioral responses when subjects are given the same dose of the drug. There are some studies
which report that MPD elicits behavioral sensitization, whereas there are other studies which report
that the same dose of MPD results in behavioral tolerance, causing further conflicts in the literature
(Barron et al., 2004; Eckerman et al., 1991; Gaytan et al., 1996, 2000; Yang et al., 2003; 2006,
2007). The aim of the this study was to first determine if there are differences in neuronal responses
between individuals, with respect to neuronal firing patterns in the ventral tegmental area (VTA),
and whether these differences are responsible for the conflicting reports on behavioral responses with
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chronic MPD exposure. I hypothesized that animals will exhibit different overall neuronal responses
depending on whether that animal exhibits behavioral sensitization or behavioral tolerance.
Furthermore, I hypothesize that an increase or a decrease in neuronal responses directly correlates to
behavioral sensitization or tolerance, respectively.
Several reviews suggest that behavioral tolerance and sensitization are phenomena in animals
that represent an enduring response to medications even after the discontinuation of drug use , and
are used as a model for drug craving and dependence (Laasko et al., 2002; Kalivas et al., 1998;
Kauer, 2004; Robinson and Berridge, 1993; Wolf, 1998). It has been previously shown that
stimulants such as cocaine, amphetamine, and MPD are able to cause dose dependent behavioral
sensitization in animals (Algahim et al., 2009; Bergheim et al., 2012; Gaytan et al., 1996, 1999;
Kalivas et al., 1988; Tang et al., 2009; Yang et al., 2003, 2011). Behavioral sensitization is defined
as the increased amplification of activity resulting from repetitive administration of psychostimulants
(Chao and Nestler, 2004; Gaytan et al., 1997; Kalivas and Stewart, 1991). Behavioral sensitization
occurs in two phases: induction and expression. In the induction phase, transient changes occur
following repetitive psychostimulant administration that subsequently result in increased behavioral
activity. The expression phase is characterized by persistent long-lasting neuronal changes that result
in sustained augmented behavioral responses despite cessation of psychostimulant use (Pierce and
Kalivas, 1997). Thus, there is an increased behavioral activity response observed when animals are
given a rechallenge exposure of the drug following a period when the drug is no longer in the
system.
Generally it is believed that behavioral sensitization occurs due to synaptic plasticity in the reward
circuit, including the CNS structures: the nucleus accumbens (NAc), prefrontal cortex (PFC),
caudate nucleus (CN), and the VTA.
The induction phase is thought to occur at glutamatergic synapses of the dopamine (DA)
neurons in the ventral tegmental area (VTA) (Kalivas and Weber, 1988; Vezina, 1993; Perugini
and Vezina, 1994; Pert, 1998). The expression of behavioral sensitization is suggested to be
due to repetitive (chronic) psychostimulant exposure causing increased glutamate transmission
and a decrease of D1 DA to GABAergic neurons in the VTA (Bonci and Williams, 1996; Pierce
7

and Kalivas, 1997; Kalivas and Duffy, 1993). Reprinted from Jones,Z.; Dafny,N. Acute and
chronic dose-response effect of methylphenidate on ventral tegmental area neurons correlated
with animal behavior. J. Neural Transm. 2013 In Press. with kind permission of Springer
Science and Business Media. Copyright © 2013, Springer Science and Business Media.
The Role of the Ventral Tegmental Area (VTA) in Response to MPD
The VTA is an extremely important area of the brain when it comes to drug use and
has a large role in the behavioral effects of psychostimulants. The VTA is a midbrain structure that is
rich in both DA and gamma amino-butyric acid (GABA) neurons (Grace and Onn; 1989) which
project to the NAc and PFC and the latter structures also send neurons back to the VTA, thus there is
communication back and forth between these structures (Figure 1). Both DA and GABA neurons in
the VTA get input mediated by GABA and glutamate. The primary afferent neurons which are
excitatory to the VTA and contain glutamate come from the PFC, while those containing GABA
originate in the NAc (Beckstead et al., 1979; Johnson and North, 1992; Kalivas and Duffy, 1995). In
addition, the VTA gets other excitatory inputs from the amygdala, laterodorsal tegmental nucleus
and the bed nucleus of the stria terminalis (Kauer, 2004). The dopaminergic neurons in the VTA coexpress GABA-ergic or glutamatergic markers and it is thought that these DA neurons are activated
by the glutamatergic inputs that originate in the PFC and specifically that these neurons are involved
in the induction of behavioral sensitization following repetitive exposure of psychostimulants
(Scheggi et al., 2002; Tang et al., 2009; Wanchoo et al., 2010). The DA neurons in the VTA that
express the glutamatergic markers do so for both the metabotropic and ionotropic receptors which in
turn include the NMDA and AMPA subtypes. In a morphological study, it has been shown that about
two-thirds of the neurons in the VTA are dopaminergic, while the remaining neurons are mostly
GABA (Nair-Roberts et al., 2008).
Subsequently, it has been shown that the mesoaccumbens projection which is formed by the
ascending VTA DA neurons to the nucleus accumbens (NAc) have been implicated with the
induction of behavioral sensitization and that the VTA plays an integral role in this phenomena
(Joyce and Rayport, 2000; Kalivas et al., 1993; Wolf, 1998). For example, in studies that have used
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amphetamine and DA D1 and NMDA receptor antagonists have shown that the VTA is responsible
for the induction phase of sensitization following repetitive exposure to psychostimulants and
perhaps the control of relapse, dependence and drug craving (Kalivas and Weber, 1988; Kalivas and
Stewart, 1991). In another study, it was shown that with repeated injection of amphetamine into the
VTA, sensitization can be produced (Vezina, 1993; Perugini and Vezina, 1994). After such
treatment, it is also possible to become sensitized to systemic morphine injections (Vezina and
Stuart, 1990). On the other hand, if DA D1 receptor antagonists or NMDA receptor antagonists are
injected into the VTA, then behavioral sensitization cannot be observed (Kalivas and Stuart, 1991).
Therefore, it is directly shown that the VTA in absolutely crucial to the development of behavioral
sensitization. Chronic stimulant use has been reported to be responsible for structurally altering areas
of the brain affected by MPD such as the CN and VTA following acute and repeated administration
of MPD. These alterations include the regulation of the transcription factors CREB and ∆Fos B, both
implemented in drug dependence (Chao and Nestler, 2004; Nestler 2004, 2008). ∆Fos B gene
expression is increased by the upregulation of ERK which has been reported to induce long-term
neuroadaptions in the brain (Shi and McGinty, 2010; Zhang et al., 2004). ∆Fos B elevation is
correlated with increased reliance to the behavioral effects and increased motivation for the drug
(Nestler, 2001; 2004; 2008). D1 receptor inhibition by blockade or ablation results in an increase in
phosphorylation of cAMP response element binding protein (CREB), inhibiting the excitatory
responses (Ferguson et al., 2010). Due to the importance of the VTA in stimulant action like that of
MPD, the VTA was chosen as the target structure of this study.
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Figure 1 shows the location of the VTA and its connections to other areas of
the reward circuit. The VTA sends connections to the prefrontal cortex as
well as the nucleus accumbens and in turn receives input from those areas.
Rights for reuse of figure obtained through Elsevier
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In this study, we strove to compare the neuronal responses and behavioral responses to acute and
chronic MPD administration and to determine whether there are any relationships which can be
made between these two types of responses. We hypothesize that animals exposed to the same dose
of MPD will exhibit different behavioral responses in that some animals will exhibit behavioral
sensitization while others will exhibit behavioral tolerance to the same dose of drug. Also, we
hypothesized that when these animals are separated based on their behavioral responses of
sensitization or tolerance, their neuronal responses will be statistically significantly different.
Therefore, the aim of this study was to examine the dose response effects of acute and chronic MPD
on VTA neurons of non-anesthetized freely moving animals previously implanted with permanent
electrodes and to evaluate the VTA neuronal activity based on the animals’ behavioral response to
chronic MPD administration. We chose to investigate this hypothesis using a rodent model, as the
relationship between drug doses (milligrams of hydrochloride salt/kilogram of body weight) and
percentage occupancy of the dopamine transporter (DAT) is identical for cocaine and MPH in both
rodents and humans (Gately et al., 1999). Previous neurophysiological studies targeting the reward
circuit independent of the animals behavioral activity show that 2.5 mg/kg MPD modulates the
neuronal activity of certain CNS sites such as the VTA, NAc, PFC, and CN following both acute and
chronic MPH exposure (Chong et al., 2012; Claussen and Dafny, 2012; Salek et al., 2012). We
believe that finding a correlation between the neuronal and behavioral properties of animals in
response to acute and chronic MPD will give us insight into why conflicting results are observed
across both animal and human studies that investigate the long term adaptations occurring in
response to chronic MPD exposure and will further the knowledge of how MPD affects the VTA.
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2 Materials and Methods
Parts of this chapter are based on Jones,Z.; Dafny,N. Acute and chronic dose-response effect of
methylphenidate on ventral tegmental area neurons correlated with animal behavior. J. Neural
Transm. 2013 In Press. Reprinted from Jones and Dafny, 2013 with kind permission of Springer
Science and Business Media. Copyright © 2013, Springer Science and Business Media.
2.1 Animals
Male Sprague-Dawley rats (N=51 adult, N=113 adolescent) at post natal of about 50 days
(adult) and 32 days (adolescent) were purchased (Harlan, Indianapolis, IN, USA) and were allowed
3-4 days of acclimation in our vivarium room on a 12 hour light/dark schedule (lights on 6:00am).
Food and water were given ad libitum. The animals were housed individually in clear acrylic
standard cages that served as both home cage and test cage for this study. The experiment was
approved by our Animal Welfare Committee and carried out in accordance with the National
Institute of Health Guide for Care and Use of Laboratory Animals.
2.2 Surgeries
Prior to surgery, two Nickel-Chromium Teflon coated (fully insulated except at tips) 60 µ in
diameter wire were twisted to make two recording electrodes for each VTA hemisphere. Each of the
four wires was secured to a 1.0 cm copper connector pin (A-M systems, INC.). On the day of
surgery, the rats were anesthetized with an intraperitoneal (i.p.) injection of 25 mg/kg pentobarbital.
The animal’s head was shaved and lidocaine hydrochloride topical gel was applied to the shaved
area. The animal was then placed in a stereotaxic apparatus where an incision was made on the scalp
and the muscle and connective tissue was removed to expose the skull. Bilateral holes were drilled
above the VTA at 2.3 mm anterior to lambda and 1 mm lateral to midline with a depth of 7.6 to 8.0
mm in the adolescent rat using the Sherwood and Timiras (1970) brain atlas coordinates. Bilateral
holes were drilled above the VTA at 6.0 mm posterior to bregma and 0.5 mm lateral from midline
with a depth of 8.5 mm, using Paxinos and Watson (1986) brain atlas coordinates for the adult
animals. Six anchor screws were inserted in the skull at vacant spots to secure the implanted
electrodes and the head plug.

12

Electrodes were then inserted individually into the brain from the skull with neuronal activity
monitored by Grass emitter Hi Z Probe connected to a Grass P511 series amplifier. When a 3:1
signal to noise ratio spike activity was obtained, the electrode was permanently secured to the skull
using web glue cyanoacrylate surgical adhesive. When the neuronal activity exhibited less than a 3:1
signal to noise ratio spike activity, the electrode was lowered in 5-10 µm increments until a 3:1 ratio
activity was observed (Chong et al., 2012; Claussen and Dafny, 2012; Dafny, 1980; 1982; Dafny and
Terkel, 1990; Salek et. al., 2012). Similar procedures were followed for the second twisted electrode
which was implanted into the VTA of the opposite hemisphere. The two copper pins from each
twisted electrode from the four recording electrodes, were inserted into Amphenol plugs which were
secured to the skull using dental acrylic cement creating the skull cap. Animals were allowed 3 to 5
days recovery after electrode implantation during which they were placed daily with their home cage
in the experimental apparatus and connected to the wireless (telemetric) head stage transmitter
(Triangle BioSystems Intl (TBSI); Durham, NC, USA) for acclimation for at least 2 hours/day to the
behavioral and electrophysiological recording systems. At the first experimental day, the adolescent
animal’s weight is around 100-120 grams and around 39-45 days post natal, while the adult animal’s
weight was between 200 and 220 grams and at about post natal 62-64 days.
2.3 Drugs
Three methylphenidate hydrochloride (MPD) (obtained from Mallinckrot Hazelwood, MO,
USA) doses of 0.6, 2.5, and 10.0 mg/kg, were used; the MPD doses were calculated as a free base
and were dissolved in 0.9% isotonic saline solution. Control injections consisted of 0.8 ml isotonic
saline solution (0.9% NaCl) administered i.p. All injections were equalized to a volume of 0.8 ml
with 0.9% saline to keep injection volumes the same for all of the animals and for all the MPD doses.
Previous MPD dose response experiments, testing behavioral and neurophysiological
sensory evoked potential procedures, from 0.1 mg/kg to 40.0 mg/kg MPD administration, found that
behavioral effects of MPD were observed from the 0.6 mg/kg MPD dosage (Algahim et al., 2009;
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Gaytan et al., 1996, 2000; Lee et al., 2009; Podet et al., 2010; Yang et al., 2003, 2006a; 2006b;
2006c; 2006d; 2007). Therefore 0.6, 2.5, and 10.0 mg/kg MPD dosages were selected for this study.
There are no universally recognized MPD dosage guidelines or blood levels to achieve
optimum dose treatment. A study of 289 patients treated with MPD (White and Yadao, 2000)
reported that the range of doses ingested was from 0.06 to 29.3 mg/kg. Approximately 2 to 3 mg/kg
i.p. MPD in rodent achieved plasma levels similar to those achieved in clinical use (Gatley et al.,
1999; Gerasimov et al., 2000). Drug effects in rodents often require higher doses (on mg/kg basis)
than humans because rodents exhibit a more rapid metabolism (Gatley et el., 1999).
2.4 Experimental Protocol
On experimental day one (ED1), rats with their home cage were placed in a Faraday testing
box to reduce noise during the recording session. The wireless (TBSI); (Fan et al., 2011) head stage
was connected to the electrode pins of the skull cap and the animals were allowed to acclimate for 30
minutes prior to the recording session. This time was used to prepare the recording software
parameters and the injections of both saline and MPD. After acclimation, the animals received a
saline injection of 0.8 ml (standardized for all injections) and the neuronal and behavioral activity
was recorded to obtain the baseline activity for one hour followed by either saline, or 0.6, 2.5 or 10.0
mg/kg MPD injection, and the behavioral and the neuronal activity recordings were resumed for an
additional hour post injection (Table 1). The wireless TBSI head stage sent neuronal activity signals
from the 4 recording electrodes to a receiver that was connected to a Cambridge Electronic Design
(CED) Cambridge England analog-to-digital converter (Micro1401-3; CED) which collected and
stored the recorded data on a PC using Spike 2.7 CED software. On ED2 through ED6 animals
received either saline or daily MPD injections similar to ED1 injection in their home cage without
recording. On ED7 through ED9 the animals underwent washout in which no injections were given
proceeded by ED10 in which a saline injection was given and the neuronal and behavioral activity
was recorded for an hour post saline injection followed by a rechallenge administration of either
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saline or MPD similar to ED1 and recordings were resumed for an additional one hour just as on
ED1 (Table 1).
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Table 1

Experimental Days
Treatment

Day 1

Days 2-6

Days 7-9

Day 10

Saline

Saline/Saline

Saline

Washout

Saline/Saline

0.6 mg/kg MPD

Washout

2.5 mg/kg MPD

Washout

10.0 mg/kg MPD

Washout

0.6 mg/kg MPD
2.5 mg/kg MPD
10.0 mg/kg MPD

Saline/0.6 mg/kg
MPD
Saline/2.5 mg/kg
MPD
Saline/10.0 mg/kg
MPD

Saline/0.6 mg/kg
MPD
Saline/2.5 mg/kg
MPD
Saline/10.0 mg/kg
MPD

Table 1 summarizes the experimental protocol. Four groups of animals were used: saline, 0.6, 2.5 and
10.0 mg/kg MPD. On experimental day 1 (ED1), animals are given an initial dose of saline and
recordings were taken for one hour followed by one of the four designated doses and recordings were
resumed for an additional hour post injection. On days 2-6, the animals are only given an injection of
the specified dose. Days 7-9 are washout days where the animal gets no injection of any kind. On
ED10, the animals are given another dose of saline for one hour followed by the designated dose for
one hour, identical to that given on ED1.
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2.5 Behavioral Recording System
Locomotor activity was recorded concomitantly with neuronal activity, using an open field
computerized animal activity system (Opto-M3, Columbus Instruments, Columbus, OH). The
animal’s home cage (40 cm in length, 20 cm in width) fit into the recording apparatus allowing the
recording of the animals in his home cage. The cage and the recording system were located inside a
Faraday box to reduce noise and any outside interference. The open field system 16 and 8 infrared
beams and their sensors on the opposite side set at 5 cm above the floor of the cage. The open field
assay has been previously described in detail (Gaytan et al., 1996, 1997a, b, 2000; Yang et al.,
2006a, 2007, 2011). In short, the activity monitoring system checked each of the sensor beams at a
100 Hz frequency to determine whether beams were interrupted. The interrupted beams were
compiled by the software and downloaded to a PC every 10 min, (i.e. 6 bins/hr). The program
organized the beam interruption into different locomotor movement indices, such as horizontal
activity (HA) which records the overall locomotor activity that used to assess the overall amount of
locomotor activity and the number of stereotypic activity (NOS) which counts the number of
repetitive movement episodes with at least one second interval before the beginning of another
episode of movements. The 6 bin counts following each hour were used for the statistical analysis
and to produce temporal graphs and histograms for total activity/hr for both the saline (baseline
activity) and the activity after MPD administration for ED1 and ED10.
2.6 Electrophysiological apparatus
A Triangle BioSystems International (TBSI) telemetric head stage weighing 4.5 g was
attached to the electrode pins of the skull cap of the rat. The head stage sent neuronal activity signals
(sampling rates up to 200 kHz) to a receiver connected to the Cambridge Electronic Design (CED)
analog-to-digital converter (Micro 1401-3; CED, Cambridge, UK) which stored the data on a PC
using the Spike 2 version 7 software for offline analysis.
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2.7 Data analysis
2.7.1 Behavioral Analysis
The locomotor activity was recorded and summed in 10 minute bins for 60 minutes after saline
injection proceeding another 60 minutes of behavioral activity counts recorded following MPD
injection (12 bins total) on ED1 and again on ED10 following saline and MPD exposure (Table 1).
1) Behavioral analysis of HA of activity following acute MPD was compared to the activity after
saline (control) at ED1; 2) the activity post saline at ED10 was compared to the activity after saline
on ED1 and 3) the chronic MPD effect was determined by comparing the activity following MPD
on ED10 to the activity after MPD at ED1 using the Critical Ratio CR Test; (C.R.) =

√

= ± 1.96 =

p < 0.05 and the student paired t-test (Chong et al., 2012; Claussen and Dafny, 2012; Salek et al.,
2012; Yang et al., 2012; Yang et al., 2006a; 2006b; 2006d; 2007). Where for example E represents
the HA after MPD administration at ED1, and C represents the HA after saline injection of ED1.
When a CR value more than 1.96 was obtained it indicated that the drug elicited significantly
increased activity i.e. behavioral sensitization and when a CR value more than -1.96 was obtained it
indicated that the drug elicited significant attenuation as compared to the initial drug effects i.e.
behavioral tolerance.
Based on the above analysis each rat was individually classified as expressing either behavioral
sensitization or tolerance and thus two sub groups were created: sensitized and tolerant/nonsensitized category. These rat subgroups were analyzed again as a group using analysis of variance
(ANOVA: treatment days and drug doses). Any statistical significance was determined with the post
hoc Fischer's LSD method. Statistical significance was set at P < 0.05 for all comparisons.
2.7.2 Spike sorting
The Spike 2 version 7 software (CED) was used for spike sorting. The data was captured by
the program (sampling rates up to 200 kHz) and processed using low and high pass filters (0.3-3
kHz). There were two window discriminator levels, one for positive-going spikes and one for
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negative-going spikes. The spikes with peak amplitudes within the window were used to create
templates using 1000 waveform data points. The parameters that were used to capture a spike
pattern allows the extraction of templates that provide high-dimensional reference points which can
be used to perform accurate spike sorting, despite some movement artifacts noise, false threshold
crossing and waveform overlap. All temporally displaced templates are compared with the incoming
spike event to find the best fitting to the selected template amplitude that yields the minimum residue
variance. When the distance between the template and waveform exceeds some threshold (80%), the
waveforms are rejected. This means that the spike sorting accuracy in the reconstructed data is about
95%. All of the parameters of spike sorting for each electrode at ED1 were stored and reused for the
activity sorting at ED10 aiming to count the same spike amplitude and pattern at ED1 and ED10
following saline and MPD administration from the same electrode. Spikes with peak amplitudes
outside these limits and spikes that didn’t fit the template were rejected.
2.7.3 Electrophysiological Data evaluation
Once the neuronal activity was sorted and counted, the activity post saline and MPD
exposure was exported to a spreadsheet to produce sequential firing rate graph spikes/sec and
counting the total neuronal activity. The initial 60 minutes following saline injection at ED1 was
used as the ED1 baseline activity. Similar calculations were done for ED10, i.e. 60 min post ED10
saline for the ED10 baseline activity and 60 min post MPD at ED10, the effect of MPD rechallenge.
The activity post MPD at ED1 compared to ED1 baseline activity was used to determine the MPD
effect. The baseline activity on ED10 was compared to the baseline activity on ED1 to find out
whether the six consecutive daily injection and the three washout days resulted in the baseline
alteration, and lastly, the effect of drug administration on ED10 was compared to the effects of drug
administration on ED1 to find out whether sensitization or tolerance was expressed.
Multiple methods were employed to find out whether MPD elicits significant effect on VTA
neuronal activity as follows: the mean firing rate after MPD treatment needs to be at least two
standard errors (S.E.) difference from the control mean firing rate. Firing rates were evaluated also
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for normality assumptions to determine parametric or non-parametric methods. To evaluate
differences between the above comparisons, the firing rates were determined to not hold normality
assumptions, so we assessed also differences in firing rates using the Critical Ration test. Critical
Ratio test ((C.R.) =

√

= ± 1.96 = p < 0.05) (C = control, E = activity after drug exposure) for the

first comparison. For the second comparison, E was the baseline at ED10 and C is the baseline at
ED1, while for the third comparison E was the data post MPD exposure at ED10 and C the data post
MPD exposure at ED1 (Chong et. al., 2012; Claussen and Dafny 2012; Dafny, 1975; 1982; Salek et.
al., 2012; Yang et al. 2006a; 2006b; 2006c).
In addition, the natural log odds ratio and an ANOVA statistical tests were used: the natural logs
ratio was utilized to determine the likelihood that VTA neuronal populations recorded from animals
expressing behavioral sensitization are the same or different from the VTA neuronal populations
recorded from animals expressing behavioral tolerance to repetitive MPD exposure. This was done
for the data obtained following the initial (acute) MPD injection compared to ED1 baseline, the
baseline neuronal activity at ED10 compared to the baseline activity at ED1, and the recording
following rechallenge of MPD at ED10 compared to the effect of initial MPD injection at ED1. To
compensate for the smaller values observed on certain days for varying doses, 0.5 was added to all
numbers for computation of the odds ratio. A number of 1 and higher in the odds ratio test indicates
a significantly higher likelihood of different responses to MPD exposure (increases or decreases in
the neuronal activity) in the neuronal populations recorded from behaviorally sensitized animals
compared to recordings from animals expressing behavioral tolerance. Conversely a number smaller
than 1 represents a less likely chance of differences between the two VTA neuronal populations
(Morris and Gardner, 1988) in response to MPD exposure.
The ANOVA statistical test with statistic value (p<0.05) was used to compare the difference
in response to MPD exposure between the neuronal population recorded from animals expressing
behavioral sensitization to the VTA neuronal population recorded from animals expressing
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behavioral tolerance to acute and chronic MPD exposure, as well as to compare the adult sensitized
animals to the adolescent sensitized animals and the same for the tolerant animals.
2.7.4 Histological verification
Upon completion of the recording at ED10, the animals were euthanized with sodium
pentobarbital. The rat was then perfused intracardially with 10% formaldehyde solution containing
3% potassium ferrocyanide. A 2mA DC current was passed through the tip of each electrode for 40
seconds to create a small lesion to identify the electrode location; the brain was extracted from the
skull and placed in 10% formaldehyde for several days. The brains were sliced in 40-60µm sections
and the position of the electrode tip was identified by the location of the electrolytic lesion in the
adolescent rat by using the Sherwood and Timiras brain atlas (1970) (Figure 2) and in the adult
animal using the Rat Brain atlas (Paxinos and Watson, 1986) (Figure 3).
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Figure 2. Histologically verified electrode tip placement in the VTA using the coordinates given in
the Sherwood and Timiras rat brain atlas 1970. The black spots are the ideal locations of the
electrode tips. Rights for reuse of figure obtained through Elsevier.
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-8.1 mm

-8.3 mm

-8.5 mm

Figure 3 reconstructs histologically verified electrode tip placement in the adult VTA using the plate
from Paxinos and Watson Rat Brain Atlas 1986. The black triangles indicate areas that are
considered VTA for histological purposes. Rights for reuse of figure obtained through Elsevier
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3 Results
3.1 Adolescent
A total of 113 adolescent rats with electrodes confirmed to be in the VTA were used in this
experiment; 11, 28, 31, and 43 rats were treated with saline (control), 0.6, 2.5, or 10.0 mg/kg MPD
respectively and 307 VTA units were recorded, 26, 81, 99, and 101 after saline, 0.6, 2.5, and 10.0
mg/kg MPD respectively.
3.2 Behavioral Results Adolescent
The overall effect of the acute MPD administration resulted in a dose response dependent
increase in locomotor activity. In addition, the baseline activity at ED10 after six daily MPD
exposures and three washout days compared to experimental day 1 (ED1) was increased. In general
the locomotor activity of all the animals after MPD rechallenge on experimental day 10 (ED10)
compared to the recording of ED1 after the initial MPD administration for the dose of 2.5 mg/kg
MPD elicited behavioral tolerance and in the higher MPD dose of 10.0 mg/kg dose the group
expressed behavioral sensitization as determined by a significant increase in behavioral activity on
ED10 following MPD compared to the behavioral activity following MPD on ED1. Eleven animals
were treated only with saline. The locomotor activity (HA) from ED10 compared to ED1 following
chronic injection of saline exhibited similar locomotor activities with minor non-significant
fluctuations in the locomotor indices evaluated following single and multiple saline injections. This
showed that neither saline, needle injection nor handling had any effect on behavioral activity
(Figure 4). Therefore any significant changes from baseline after drug treatment were due to the
effects of MPD. For the adolescent behavioral figures, Sensitized= summarizes the total distance of
animals expressing behavioral sensitization and Tolerance= summarizes the total distance of the
individual animals that express behavioral tolerance.
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Figure 4 summarizes the total distance activity of the control groups (N=11) after injection of
saline on experimental day 1 (ED1) and ED10. For each experimental day, saline was first
injected and the behavioral activity was recorded for one hour. Following this, another
injection of saline was given and again the animals were recorded for another hour.
Comparison between the 2nd injections to the first for both days, showed no significant
differences.
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3.2.1 Adolescent 0.6 mg/kg MPD
Twenty-eight animals were treated with 0.6 mg/kg MPD and when grouped together, no
significant changes in behavioral activity were noted for either the acute or the chronic exposures to
MPD or when comparing the baseline activity on ED10 after six daily 0.6 mg/kg MPD exposures
and three washout days, to the baseline activity recorded on ED1 using the ANOVA test (Fig 5 All).
When the animals were separated based on their individual responses to chronic MPD using the C.R.
test, 14 individual animals failed to respond significantly to the initial (acute) MPD exposure at ED1,
but expressed significant (p < 0.05) increases in their locomotor activity using the ANOVA test i.e.
they expressed behavioral sensitization to MPD rechallenge exposure at ED10 (Fig 5 0.6 mg/kg
MPD Sensitized). Fourteen individual animals exhibited behavioral tolerance to 0.6 mg/kg MPD
rechallenge at ED10 compared to MPD at ED1 using the C.R. test. These animals at ED1 exhibited
significant (p < 0.05) increases in their behavioral activity following acute MPD exposures and on
ED10 exhibited a significant (p < 0.05) decrease in their activity in response to the MPD rechallenge
compared to activity post MPD at ED1 using the ANOVA test (Fig 5 0.6 mg/kg MPD Tolerance).
We were able to show that 0.6 mg/kg MPD can induce both behavioral sensitization and behavioral
tolerance to different animals.
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Figure 5 summarizes the behavioral activity following acute and chronic injection of 0.6 mg/kg
MPD. The activity for all the animals grouped together (N=28) is shown on the left with
comparisons between the ED1 baseline activity, the ED1 MPD injection, and the ED10 MPD
injection compared to that post MPD on ED1. For the middle and right sides of the histogram, the
animal groups are broken down into two groups: those animals exhibiting behavioral sensitization
(N=14) and those exhibiting behavioral tolerance (N=14). For these two groups, the same
comparisons were made as the ‘all’ group. All= summarizes the total distance of all the animals. *=
indicates significant (p < 0.05) difference between the effect of the initial MPD exposure at ED1 to
their baseline activity. ∆= indicates significant difference between the ED10 activity post MPD to the
activity of ED1 post MPD exposure.
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3.2.2 Adolescent 2.5 mg/kg MPD
Thirty-one animals were treated with acute and chronic 2.5 mg/kg MPD. Acute MPD
exposure elicited significant (p < 0.05) increases in activity while repetitive (chronic) 2.5 mg/kg
MPD elicited significant (p < 0.05) decreases in activity at ED10 compared to the activity elicited by
the initial MPD exposure at ED1 i.e., tolerance to MPD rechallenge (Fig 6 2.5 mg/kg MPD All).
When the animals were separated by their individual behavioral responses to MPD, 22 out of the 31
animals exhibited individually behavioral sensitization using the C.R. test and as a group using the
ANOVA test had significant (p < 0.05) increases to acute administration of MPD, and following
rechallenge dose of 2.5 mg/kg MPD on ED10 exhibited further significant (p < 0.05) increase
compared to that observed on ED1 i.e. expressing behavioral sensitization (Fig 6 2.5 mg/kg MPD
Sensitized). Nine individual animals each exhibited behavioral tolerance using the C.R. test. These
animals showed a significant (p < 0.05) increase in activity to acute administration of MPD, and a
significant decrease in activity following rechallenge to MPD on ED10 compared to the effect of
MPD on ED1 using the ANOVA test (Figure 6 2.5 mg/kg Tolerance). Those animals that exhibited
tolerance to MPD rechallenge at ED10 responded to acute MPD significantly (p <0.05) higher than
the animals that expressed behavioral sensitization (Fig 6 2.5 mg/kg MPD).
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Figure 6 summarizes the behavioral activity following acute and chronic injection of 2.5
mg/kg MPD. The activity for all the animals grouped together (N=31) is shown on the left
with comparisons between the ED1 baseline activity, the ED1 MPD injection, and the ED10
MPD injection compared to that post MPD on ED1. For the middle and right sides of the
histogram, the animal groups are broken down into two groups: those animals exhibiting
behavioral sensitization (N=22) and those exhibiting behavioral tolerance (N=9). For these
two groups, the same comparisons were made as the ‘all’ group. All= summarizes the total
distance of all the animals. *= indicates significant (p < 0.05) difference between the effect
of the initial MPD exposure at ED1 to their baseline activity. ∆= indicates significant
difference between the ED10 activity post MPD to the activity of ED1 post MPD exposure.
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3.2.3 Adolescent 10.0 mg/kg MPD Behavior
Forty-three animals were treated with 10.0 mg/kg MPD and when grouped together, these
animals exhibited a significant (p < 0.05) increase in locomotor activity to the acute administration
of MPD on ED1. Following MPD rechallenge at ED10, these animals exhibited further significantly
(p < 0.05) increased locomotor activity using the ANOVA test (Fig 7, 10.0 mg/kg MPD, All). When
the animals were separated based off of their individual responses to 10.0 mg/kg MPD using the C.R.
test, 37 animals that individually exhibited behavioral sensitization responded significantly (p <
0.05) to acute MPD exposure by increasing their behavioral activity and had further significant (p <
0.05) increases in their locomotor activity following rechallenge MPD at ED10 compared to ED1
activity post MPD exposure using the ANOVA test (Fig 7 10.0 mg/kg MPD Sensitized). Six
individual animals responded to acute MPD exposure by increasing their locomotor activity and the
MPD exposure at ED10 resulted in significantly (p < 0.05) less activity compared to the initial MPD
exposure using the ANOVA test i.e., these animals expressed behavioral tolerance to MPD
rechallenge at ED10 compared to the initial acute MPD exposure at ED1 (Fig 7 10.0 mg/kg MPD
Tolerance).
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Figure 7 summarizes the behavioral activity following acute and chronic injection of 10.0
mg/kg MPD. The activity for all the animals grouped together (N=43) is shown on the left
with comparisons between the ED1 baseline activity, the ED1 MPD injection, and the ED10
MPD injection compared to that post MPD on ED1. For the middle and right sides of the
histogram, the animal groups are broken down into two groups: those animals exhibiting
behavioral sensitization (N=37) and those exhibiting behavioral tolerance (N=6). For these
two groups, the same comparisons were made as the ‘all’ group. All= summarizes the total
distance of all the animals. *= indicates significant (p < 0.05) difference between the effect
of the initial MPD exposure at ED1 to their baseline activity. ∆= indicates significant
difference between the ED10 activity post MPD to the activity of ED1 post MPD exposure.
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3.3 Adults
Parts of this chapter are based on Jones,Z.; Dafny,N. Acute and chronic dose-response effect of
methylphenidate on ventral tegmental area neurons correlated with animal behavior. J. Neural
Transm. 2013 In Press. Reprinted from Jones and Dafny, 2013 with kind permission of Springer
Science and Business Media. Copyright © 2013, Springer Science and Business Media.

A total of 51 rats with 111 electrodes confirmed to be in the VTA were used in this experiment.
Twenty, 14, 7, and 10 rats were treated with saline, 0.6, 2.5, and 10.0 mg/kg MPD respectively and
361 units were recorded, 76, 132, 62, and 91 after saline, 0.6, 2.5, and 10.0 mg/kg MPD respectively.
3.4 Behavioral Results Adult
Control: Twenty animals were treated only with saline. Following acute and repetitive saline
injection, all animals expressed similar locomotor activity following the 2nd saline injection
compared to the first on ED1. This showed that saline and handling had no effect on the rats’
behavioral activity. Therefore the activity after saline injection at ED1 can be used and was used as
the control for the MPD effects, i.e., any significant changes due to drug exposure were due to the
effects of MPD.
3.4.1 Adult 0.6 mg/kg MPD
Fourteen animals were treated with 0.6 mg/kg MPD, the ANOVA test showed no significant changes
in locomotor activity after acute or chronic 0.6 mg/kg MPD or when the baseline activity at ED10
(after 6 daily 0.6 mg/kg MPD and 3 washout days) was compared with ED1 baseline (Fig 8Aa).
When these 14 animals were divided based on their individual behavioral responses to chronic MPD
exposure, 3 animals at ED10 following MPD exposure exhibited significant (p < 0.05) increases in
their locomotion compared to the activity following MPD injection on ED1 (Fig 8 Ab). These 3
animals at ED1 responded to MPD by significant (p < 0.05) decreases by 52% in their locomotor
activity compared to their ED1 baseline (Fig 8 Ab). The baseline locomotor activity at ED10 after 6
daily injections of 0.6 mg/kg MPD and 3 washout days was significantly (p < 0.05) elevated by 38%
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compared to the baseline at ED1 (Fig 8 Ab). The remaining 11 animals treated with 0.6 mg/kg MPD
showed reduction in their locomotor activity at ED10 post MPD compared to ED1 post MPD
exposure, but this attenuation appears to be non-significant as a group. These animals did not
respond significantly to acute 0.6 mg/kg MPD and their ED10 baseline behavioral activity compared
to ED1 baseline behavioral activity was relatively unchanged (Fig 8 Ac).
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Figure 8 shows the horizontal activity (HA) traveled data following 0.6 mg/kg MPD dose.
The top histogram (Aa) summarizes all the animals (N = 14). In addition, data was broken
down into those animals that exhibited behavioral sensitization (N = 3) (Ab) and those
animals that exhibited behavioral tolerance (N = 11) (Ac) to chronic MPD exposure
respectively. For each group, the HA of ED1 after MPD exposure is compared to ED1
Baseline activity; the ED10 Baseline HA is compared to ED1 Baseline HA; and the HA
activity on ED10 following MPD exposure is compared to the ED1 HA post MPD exposure.
ED - experimental day; BL – baseline; MPD – methylphenidate; * - P < 0.05.
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3.4.2 Adult 2.5 mg/kg MPD
Seven animals were treated with acute and chronic 2.5 mg/kg MPD, and when grouped
together for analysis of their behavioral activity, it was observed (ANOVA test) that all the animals
exhibited significant (p < 0.05) increases in their locomotion following the initial (acute) 2.5 mg/kg
MPD exposure at ED1 (Fig 9 Bd). However, the activity post MPD exposure at ED10 compared to
activity post MPD at ED1, as well as the baseline activity at ED10 compared to the baseline at ED1,
was about the same, i.e. was not significantly different (Fig 9 Bd). When these seven rats were
evaluated individually using the C.R. test and then grouped based on their individual responses to
chronic MPD exposure, 3 animals exhibited behavioral sensitization (using the ANOVA test, p <
0.05). The acute 2.5 mg/kg MPD to these 3 animals elicited non-statistically significant increases in
locomotion (Fig 9 Be). The baseline activity at ED10 of these 3 animals compared to baseline at
ED1 exhibited non-significant attenuation, and there were increases in their locomotor activity at
ED10 compared to ED1 post MPD exposure, but due to a large standard error and small N, it was not
significant (Fig 9 Be). The remaining 4 rats that individually exhibited a decrease in their locomotor
activity (p < 0.05) following chronic MPD exposure, i.e. exhibited behavioral tolerance. Their
behavioral response to the initial (acute) MPD was robustly (p < 0.05) increased (Fig 9 Bf) and the
baseline activity of this group at ED10 compared to ED1 baseline exhibited a non-significant
difference. The activity following chronic MPD exposure at ED10 compared to the effect of MPD on
ED1 (Fig 9 Bf) after 2.5 mg/kg MPD exposure as a group, exhibited a non-significant decrease in
their behavioral activity.
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Figure 9 shows the horizontal activity (HA) traveled data following 2.5 mg/kg MPD dose.
The top histogram (Bd) summarizes all the animals (N = 7). In addition, data was broken
down into those animals that exhibited behavioral sensitization (N = 3) (Be) and those
animals that exhibited behavioral tolerance (N = 4) (Bf) to chronic MPD exposure
respectively. For each group, the HA of ED1 after MPD exposure is compared to ED1
Baseline activity; the ED10 Baseline HA is compared to ED1 Baseline HA; and the HA
activity on ED10 following MPD exposure is compared to the ED1 HA post MPD exposure.
ED - experimental day; BL – baseline; MPD – methylphenidate; * - P < 0.05.
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3.4.3 Adult 10.0 mg/kg MPD
The 10 animals treated with 10.0 mg/kg MPD exhibited a significant (p < 0.001) increase in
locomotor activity by 580% compared to their baseline arbitrarily set at 100% (Fig 10 Cg). The
ED10 baseline activity remained the same compared to the initial baseline activity at ED1. MPD
exposure at ED10 compared to the initial MPD exposure at ED1 elicits similar effects (Fig 10 Cg).
When the animals were analyzed individually based on their chronic response to the drug to the
acute effect, 5 of the animals exhibited significant (p < 0.05) behavioral sensitization (Fig 10 Ch),
and 5 animals exhibited a significant (p < 0.05) reduction in their locomotor activity (Fig 10 Ch, Ci).
Those individual animals that exhibit behavioral sensitization exhibited significantly (p < 0.05)
increased responses to MPD in response to the acute dose of 10.0 mg/kg by 487% (Fig 10 Ch). The
baseline activity at ED10 compared to ED1 baseline was increased, but non-significantly. The
chronic effect of the drug at ED10 was compared to the initial MPD exposure at ED1, there was a
significant (p < 0.05) increase in activity by 177% (Fig 10 Ch). The 5 animals that individually
exhibited behavioral tolerance in response to 10.0 mg/kg MPD exhibited a significant (p < 0.05)
increase in response to acute drug on ED1 by 665%. Their acute response to MPD was significantly
(p < 0.05) higher compared to those animals in the sensitized group (Fig 10 Ci). The baseline activity
of these 5 tolerant rats at ED10 was similar to ED1 baseline. In response to chronic MPD on ED10
compared to ED1 post MPD, the animals exhibited a decrease in activity, but this reduction in
activity was not significant due to a large SE (Fig 10 Ci).
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Figure 10 shows the horizontal activity (HA) traveled data following 10.0 mg/kg MPD dose.
The top histogram (Cg) summarizes all the animals (N = 10). In addition, data was broken
down into those animals that exhibited behavioral sensitization (N= 5) (Ch) and those
animals that exhibited behavioral tolerance (N = 5) (Ci) to chronic MPD exposure
respectively. For each group, the HA of ED1 after MPD exposure is compared to ED1
Baseline activity; the ED10 Baseline HA is compared to ED1 Baseline HA; and the HA
activity on ED10 following MPD exposure is compared to the ED1 HA post MPD exposure.
ED - experimental day; BL – baseline; MPD – methylphenidate; * - P < 0.05.
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3.5 Comparison between Adolescent and Adult animal behavior
When comparing the adult to the adolescent behavioral following MPD administration using
an ANOVA test, there were no significant differences between the two groups for all three doses for
both ED1 and ED10. However, when they were separated out based on behavior, there were
significant differences between the adult and adolescents. For the tolerant animals, there were
significant differences between adults and adolescents for 2.5 and 10.0 mg/kg MPD on both ED1 and
ED10 (F: 7.194, P: 0.05; F: 10.466, P: 0.03; F: 9.908, P: 0.01; F: 12.832, P: 0.007). For the sensitized
animals, there were no significant differences most likely due to a low N, however, near significance
was seen for the 0.6 and 10.0 mg/kg MPD doses on ED10.
3.6 Neuronal Activity Adolescent
Two hundred and eighty-one VTA units were recorded following acute and chronic MPD
exposure. Fifty-nine percent (165/281) of the VTA units exposed to acute (0.6, 2.5, or 10.0 mg/kg)
MPD responded significantly (p < 0.05) to the drug at ED1 by changing their firing rate compared to
their baseline activity and the majority of the VTA responsive units, 73% (121/165), exhibited
significant (p < 0.05) increases in their neuronal firing rates in response to the initial (acute) MPD
exposure. Seventy percent (197/281) of the units exhibited significant changes in their baseline
activity at ED10, after six daily MPD injections and 3 washout days (see Table 1), compared to ED1
baseline, and 62% (122/197) of them exhibiting an increase in their neuronal activity. At ED10, 68%
(192/281) of the VTA units responded significantly (p < 0.05) to MPD rechallenge by changing their
firing compared to the acute MPD exposure at ED1 and the majority of them, 62% (118/192),
exhibited significant (p < 0.05) increases in their neuronal activity following MPD exposure at ED10
compared to the effect of MPD exposure at ED1.
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Figure 11 is a representative histogram showing the baseline (BL) neuronal firing rates of adolescent
VTA neurons on ED1 and the baseline activity at ED10 after six daily MPD exposure and three
washout days. In Part A, the baseline activity (BL) is shown for ED1 and then again on ED10. This
animal’s baseline activity was potentiated after the 6 days of MPD exposure and 3 washout days. In
Part B, the baseline activity is shown for ED1 and again for ED10 expressing attenuation in their
activity following 6 days of MPD exposure and 3 washout days.
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3.6.1 Adolescent VTA Neuronal (0.6 mg/kg)
The neuronal activity following 0.6 mg/kg MPD was recorded from 81 VTA units in 28
animals. Only 38% (31/81) of the VTA units responded to acute 0.6 mg/kg MPD exposure and of
those responding units, 55% (17/31) exhibited an increase in their firing rate. In addition, when
comparing the baseline neuronal activity on ED10 to baseline activity at ED1, 51% (41/81) of the
units exhibited a significant (p < 0.05) change in their firing rate, with 51% (21/51) exhibiting a
significant (p < 0.05) decrease in their firing rate. Upon MPD rechallenge at ED10 compared to the
activity post MPD on ED1, 47% (38/81) of VTA units responded significantly (p < 0.05) different by
changing their firing rate, with 66% (25/38) of them exhibiting an increase in firing rate (Table 2A).
3.6.2 Adolescent VTA neuronal based on behavior (0.6 mg/kg)
Fifty four VTA units were recorded from 14 animals that exhibited behavioral tolerance.
Following acute administration of MPD, 41% (22/54) of the VTA units responded significantly (p <
0.05) to the drug by changing their firing rate, with 55% (12/22) of these responding VTA units
exhibiting a decrease in their firing rates. Comparing the baseline activity of ED10 after six daily
MPD exposures and three washout days to that of ED1 shows that 59% (32/54) of the units changed
their firing rate significantly (p < 0.05), with 56% (18/32) of those units exhibited an increase in their
firing rates. Upon MPD rechallenge at ED10, 54% (29/54) of the VTA units responded with
significant (p < 0.05) changes in their firing rate and from these responding units, 62% (18/29) of
them exhibited significantly (p < 0.05) increased firing rates following MPD exposure on ED10
compared to that observed following MPD exposure at ED1 (Table 2C).
Twenty seven VTA units were recorded from 14 animals that exhibited behavioral sensitization to
0.6 mg/kg MPD. Only 33% (9/27) of the units responded to MPD administration on ED1 and on
ED10 and of these responding VTA units, 78% responded with an increase in their neuronal activity
(Table 2B). When the baseline activity on ED10 was compared to ED1 baseline activity, 33% (9/27)
of the units exhibited significant (p < 0.05) change in their firing rate and of these VTA units, 66%
exhibited an increase in their neuronal activity on ED10, after six daily MPD injections and 3
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washout days, compared to ED1 baseline activity (Table 2B). Upon MPD rechallenge at ED10, 33%
(9/27) of the VTA units responded with significant (p < 0.05) changes in their firing rate compared
to the activity post MPD exposure on ED1 and of these responding units, 78% (7/9) of them
exhibited further significantly (p < 0.05) increased firing rates (Table 2B).
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0.6 mg/kg MPD

Acute (ED1)

Baseline (ED10
to ED1)

Rechallenge
(ED10)

↑

17 (21%)

20 (24.7%)

25 (30.9%)

↓

14 (17.3%)

21 (25.9%)

13 (16%)

↔

50 (61.7%)

40 (49.4%)

43 (53.1%)

↑

7 (25.9%)

6 (22.2%)

7 (25.9%)

↓

2 (7.4%)

3 (11.1%)

2 (7.4%)

↔

18 (66.7%)

18 (66.7%)

18 (66.7%)

↑

10 (18.5%)

14 (25.9%)

18 (33.3%)

↓

12 (22.2%)

18 (33.3%)

11 (20.4%)

↔

32 (59.3%)

22 (40.8%)

25 (46.3%)

Subject Group

A) Total
N= 81

B) Rats
Exhibiting
Behavioral
Sensitization
N= 27

C) Rats
Exhibiting
Non-Sensitized
Behavior
N= 54

Table 2 summarizes the VTA neuronal activity following 0.6 mg/kg MPD administration. In part A,
all of the neuronal units are grouped together. The unit response is shown as either an increase in
activity, decrease in activity or no change. Data is shown for the acute administration of MPD on
ED1, the baseline activity on ED10 compared to ED1 baseline activity, and the rechallenge dose of
MPD on ED10 after 6 daily injections and 3 washout days. In part B, the data is shown for the
animals which exhibited behavioral sensitization, and in part C, the data is shown for the animals
which exhibited behavioral tolerance.
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3.6.3 Adolescent VTA Neuronal (2.5 mg/kg)
The neuronal activity following 2.5 mg/kg MPD was recorded for 99 VTA units from 31
animals. Fifty-five percent (54/99) of these units responded to the acute administration of the drug by
significantly (p < 0.05) changing their firing rates, 59% (31/54) of these responding VTA units
responded with a significant (p < 0.05) increase in their firing activity. When comparing the ED10
baseline activity to the ED1 baseline activity, 64% (63/99) of the units exhibited significant (p <
0.05) changes in their activity, with 68% (40/63) of them exhibiting a significant (p < 0.05) increase
in their ED10 baseline activity compared to ED1 baseline activity. In response to MPD rechallenge
on ED10, 64% (63/99) of the units responded significantly (p < 0.05) to the drug, the majority of
these responding units 68% (43/63) responded to MPD rechallenge with further significant increases
in their neuronal activity (Table 3A).
3.6.4 Adolescent VTA neuronal based on behavior (2.5 mg/kg)
Forty VTA units were recorded from 9 animals that exhibited behavioral tolerance.
Following acute administration of MPD, only 40% (16/40) of the VTA units responded significantly
to the drug with 56% (9/16) of these responding units exhibiting significant (p < 0.05) decreases in
their firing rates. Comparing baseline activity on ED10 to that of ED1 baseline activity, 40% (16/40)
of the units exhibited significant (p < 0.05) changes in their baseline firing rate after the six daily
MPD exposures and three washout days, with half of them exhibiting decreases in their firing rates
and the other half exhibiting an increase in their baseline firing rate (Table 3C). Upon MPD
rechallenge at ED10, 45% (18/40) of the units responded with significant (p < 0.05) changes in their
firing rates compared to the activity post MPD exposure on ED1 and of these responding VTA units,
61% (11/18) of them exhibited significantly (p < 0.05) increased firing rates following 2.5 mg/kg
MPD at ED10 compared to MPD exposure at ED1 (Table 3C).
Fifty nine VTA units were recorded from 22 animals that exhibited behavioral sensitization to 2.5
mg/kg MPD. In response to acute exposure of 2.5 mg/kg MPD, 64% (38/59) of the units responded
to drug administration by significantly (p < 0.05) changing their firing rate and of these 38
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responsive VTA units, 63% (24/38) responded to MPD with significant (p < 0.05) increases in their
neuronal activity. When baseline activity on ED10 was compared to ED1 baseline activity, 80%
(47/59) of the units exhibited a significant (p < 0.05) change in their baseline activity after the six
daily MPD exposures and three washout days and of these 47 VTA units, 68% (32/47) exhibited an
increase in their ED10 baseline neuronal activity compared to ED1 baseline activity. When given a
rechallenge dose of 2.5 mg/kg MPD on ED10, 76% (45/59) of the units responded significantly (p <
0.05) to the drug compared to the activity post MPD exposure on ED1 and of the 45 responding
VTA units, 71% (32/45) exhibited significant (p < 0.05) increases in their firing rates to MPD
rechallenge (Table 3B) (Figure 12).
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Figure 12 is a representative histogram showing the neuronal activity post MPD exposure on ED1
and ED10. In Part A, 2.5 mg/kg MPD rechallenge exposure at ED10 compared to ED1 elicited
further potentiation as a result of 6 days of daily MPD exposure, and 3 washout days. Part B is VTA
representative of units showing the neuronal activity post MPD on ED1 and again on ED10 where
the neuronal activity is on ED10 attenuated following 6 days of MPD (2.5 mg/kg) exposure,
followed by 3 washout days and MPD rechallenge compared to ED1 post MPD exposure. At the top
is 20 superimposed analog neuronal spike activity, showing that the spike recorded post MPD on
ED1 is similar to the spike post MPD rechallenge on ED10.
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2.5 mg/kg MPD
Subject Group

Acute (ED1)

Baseline (ED10

Rechallenge

to ED1)

(ED10)

↑

31 (31.3%)

40 (40.4%)

43 (43.4%)

↓

23 (23.2%)

23 (23.2%)

20 (20.2%)

↔

45 (45.5%)

36 (36.4%)

36 (36.4%)

↑

24 (40.7%)

32 (54.2%)

32 (54.2%)

↓

14 (23.7%)

15 (25.4%)

13 (22.1%)

N= 59

↔

21 (35.6%)

12 (20.4%)

14 (23.7%)

C) Rats

↑

7 (17.5%)

8 (20%)

11 (27.5%)

↓

9 (22.5%)

8 (20%)

7 (17.5%)

↔

24 (60%)

24 (60%)

22 (55%)

A) Total
N= 99

B) Rats
Exhibiting
Behavioral
Sensitization

Exhibiting
NonSensitized
Behavior
N= 40

Table 3 summarizes the VTA neuronal activity following 2.5 mg/kg MPD administration. In part A,
all of the neuronal units are grouped together. The unit response is shown as either an increase in
activity, decrease in activity or no change. Data is shown for the acute administration of MPD on
ED1, the baseline activity on ED10 compared to ED1 baseline activity, and the rechallenge dose of
MPD on ED10 after 6 daily injections and 3 washout days. In part B, the data is shown for the
animals which exhibited behavioral sensitization, and in part C, the data is shown for the animals
which exhibited behavioral tolerance.
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3.6.5 Adolescent VTA Neuronal (10.0 mg/kg)
The neuronal activity following 10.0 mg/kg MPD was recorded from 101 VTA units in 43
animals. The majority, 72% (73/101) of these VTA units following 10.0 mg/kg MPD exposure
responded significantly (p < 0.05) by changing their firing rate, 91% (73/80) of the responding VTA
units, exhibited a significant (p < 0.05) increase in their neuronal activity to MPD exposure (Table
4A). When comparing the baseline neuronal activity of ED10 to the baseline activity of ED1, 92%
(93/101) of these units exhibited significant (p < 0.05) changes in their ED10 neuronal firing rate,
and 67% (62/93) of these units exhibited a significant (p < 0.05) increase in their neuronal activity.
When MPD rechallenge was given on ED10, 90% (91/101) of the VTA units responded by
significantly (p < 0.05) changing their firing rate compared to the activity from acute MPD exposure
at ED1, and of those responding units, 55% (50/91) of them exhibited a further significant (p < 0.05)
increase in their activity compared to the initial effect of 10.0 mg/kg MPD at ED1 (Table 4A).
3.6.6 Adolescent VTA neuronal based on behavior (10.0 mg/kg)
Twenty VTA units were recorded from 6 animals that exhibited behavioral tolerance.
Following acute administration of MPD, 65% (13/20) of these VTA units responded significantly (p
< 0.05) to the drug by changing their firing rate with 62% (8/13) of these responding VTA units
exhibiting significant (p < 0.05) increases in their firing rates following MPD exposure. Comparing
baseline activity on ED10 to the baseline activity at ED1 reveals that 90% (18/20) of the units
changed their firing rate significantly (p < 0.05) after the six daily MPD exposures and three washout
days, with 56% (10/18) of them exhibiting a significant (p < 0.05) decrease in their neuronal firing
rates. Upon MPD rechallenge at ED10, 85% (17/20) of the units responded with significant (p <
0.05) changes in their firing rate and of these responding VTA units, 59% (10/17) of them exhibited
further significant (p < 0.05) decreases in their firing rates compared to the effect elicited by the
initial MPD exposure (Table 4C).
Eighty one VTA units were recorded from 37 animals that exhibited behavioral sensitization. In
response to acute exposure of MPD, the majority of these units, 83% (67/81) responded to the drug
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administration by significantly (p < 0.05) changing their firing rate and of these responding units,
97% (65/67) responded significantly (p < 0.05) with an increase in their neuronal activity. When the
baseline activity on ED10 was compared to the ED1 baseline activity, 93% (75/81) of the VTA units
exhibited significant (p < 0.05) changes in their firing rate at ED10 and of these 75 VTA units, 72%
(54/75) exhibited significant (p < 0.05) increases in their neuronal activity at ED10 compared to ED1
baseline neuronal activity. When given a rechallenge dose of 10.0 mg/kg MPD on ED10, 91%
(74/81) of the VTA units responded significantly (p < 0.05) to the drug by changing their firing rate
and of these responding 74 VTA units, 58% (43/74) exhibited further significant (p < 0.05) increases
in their firing rate at ED10 when compared to the effect of MPD on ED1 (Table 4B) (Fig 13).
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Figure 13 is a representative histogram showing VTA neuronal activity post saline injection
i.e. the baseline (BL) activity and the activity post 10.0 mg/kg MPD administration. The drug
was injected at 60 minutes post saline. In Part A, VTA neuronal activity following acute MPD
exhibits a potentiation of neuronal activity. In contrast, Part B shows VTA neuronal activity
units exhibiting attenuation following MPD administration.
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10.0 mg/kg

Subject Group

Acute (ED1)

Baseline (ED10

Rechallenge

to ED1)

(ED10)

↑

73 (73.3%)

62 (61.4%)

50 (49.5%)

↓

7 (6.9%)

31 (30.7%)

41 (40.6%)

↔

21 (20.8%)

8 (7.9%)

10 (9.9%)

↑

65 (80.2%)

54 (66.7%)

43 (53.1%)

↓

2 (2.5%)

21 (25.9%)

31 (38.3%)

N=81

↔

14 (17.3%)

6 (7.4%)

7 (8.6%)

C) Rats

↑

8 (40%)

8 (40%)

7 (35%)

↓

5 (25%)

10 (50%)

10 (50%)

↔

7 (35%)

2 (10%)

3 (15%)

A) Total
N= 101

B) Rats
Exhibiting
Behavioral
Sensitization

Exhibiting
Non-Sensitized
Behavior
N= 20

Table 4 summarizes the VTA neuronal activity following 10.0 mg/kg MPD administration. In part A,
all of the neuronal units are grouped together. The unit response is shown as either an increase in
activity, decrease in activity or no change. Data is shown for the acute administration of MPD on
ED1, the baseline activity on ED10 compared to ED1 baseline activity, and the rechallenge dose of
MPD on ED10 after 6 daily injections and 3 washout days. In part B, the data is shown for the
animals which exhibited behavioral sensitization, and in part C, the data is shown for the animals
which exhibited behavioral tolerance.

51

3.7 Neuronal Activity Adult
A total of 321 units were histologically confirmed to be recorded from the VTA and
exhibited similar amplitude and wave form at ED1 and ED10. Thirty-six VTA units were recorded
following acute and repetitive saline injection. Two units showed decreased activity at ED1; the
baseline activity of one VTA unit at ED10 compared to ED1 baseline exhibited a decrease in
activity, and one VTA unit exhibited an increase in activity at ED10 following saline injection
compared to ED1 baseline activity. This observation revealed that the saline injections and animal
handling did not alter the neuronal activity of VTA neurons.
Two hundred and eighty-five VTA units were recorded following acute and chronic MPD
exposure. Seventy-six percent (217/285) of the VTA units exposed to acute (0.6, 2.5 or 10.0 mg/kg)
MPD responded significantly (p < 0.05) to MPD at ED1 and the majority, (61%; 133/217) of these
responding units exhibited significant (p < 0.05) increases in their neuronal firing rates. Ninety-six
percent (274/285) of the total units expressed significant changes in their baseline activity at ED10
compared to ED1 with 65% (178/274) exhibiting a decrease in their baseline activity. At ED10 95%
(272/285) of the VTA units responded significantly (p < 0.05) to MPD rechallenge compared to
activity post MPD exposure on ED1 where the majority, 60% (163/272), exhibited a significant (p <
0.05) decrease in their neuronal activity.

3.7.1 Adult VTA Neuronal (0.6 mg/kg)
The neuronal activity of 132 VTA units were recorded after acute and chronic administration
of 0.6 mg/kg MPD; 71% (93/132) of the VTA units responded significantly (p < 0.05) to the initial
exposure of the drug (Table 5A Acute) by changing their firing rates compared to their baseline
firing rate. Most of the units, 94% (124/132), exhibited significant (p < 0.05) changes in their ED10
baseline activity after six daily MPD injections and three washout days compared to their ED1
baseline (Table 5A Saline). At ED10, upon MPD rechallenge compared to the initial MPD exposure
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at ED1, 91% (120/132) of the VTA units exhibited significant (p < 0.05) changes in their neuronal
activity (Table 5A Rechallenge).
Of the 93 responsive VTA units to the initial (acute) MPD exposure on ED1 (Table 6A), the
majority, 57% (53/93), exhibited a significant (p < 0.05) decrease in firing rate in response to acute
MPD exposure (Table 6A Acute). Of the VTA units that exhibited significant change at ED10
baseline compared to ED1 baseline activity, the majority 60% (75/124) showed a significant (p <
0.05) decrease in baseline activity (Table 6A Saline). Following rechallenge of 0.6 mg/kg MPD at
ED10 compared to the initial MPD injection at ED1, the majority of the responding units, 52%
(62/120), responded to the drug by attenuating their neuronal activity (Table 3A Rechallenge). The
27 VTA units that did not respond to MPD exposure on ED1, exhibited a significant (p < 0.05)
change in their ED10 baseline as well as in response to MPD rechallenge at ED10 after the six daily
injections and three washout days (Table 6A All).

3.7.2 Adult VTA neuronal based on behavior (0.6 mg/kg)
The neuronal activity of 110 VTA units was recorded from animals that exhibited behavioral
tolerance following acute and chronic 0.6 mg/kg MPD administration. The majority, 67% (74/110)
of them responded to acute administration of MPD (Table 5A Tolerance Acute), while 94%
(103/110) exhibited significant (p < 0.05) changes in their ED10 baseline compared to their ED1
baseline (Table 5A Tolerance Saline). At ED10 upon rechallenge with 0.6 mg/kg MPD compared to
post MPD given at ED1, the majority 89% (98/110) of these VTA units exhibited significant (p <
0.05) changes in their neuronal activity (Table 5A Tolerance Rechallenge).
Of the responding 74 VTA units to acute MPD on ED1, the majority, 54% (40/74) exhibited
a significant (p < 0.05) increase in neuronal firing rate in response to MPD (Table 6A Tolerance
Acute; Fig 14B). Of the 103 VTA units that exhibited significant change at ED10 baseline compared
to ED1 baseline activity, the majority, 59% (61/103) showed a significant (p < 0.05) decrease in their
neuronal activity (Table 6A Tolerance Saline). Upon rechallenge of 0.6 mg/kg MPD on ED10
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compared to the initial effect of MPD at ED1, 51% (50/98) of the responsive VTA units exhibited a
significant (p < 0.05) increase in their neuronal activity (Table 6A Rechallenge). The 24 units that
did not respond to 0.6 mg/kg MPD on ED1 (Table 5A Tolerance Acute), exhibited a significant (p <
0.05) change in their ED10 baseline activity compared to ED1 baseline activity as well as to MPD
rechallenge at ED10 after six daily MPD injections and three washout days compared to ED1 post
MPD administration.
The neuronal activity of 22 VTA units was recorded from animals that exhibited behavioral
sensitization following acute and chronic 0.6 mg/kg MPD administration. The majority of them, 86%
(19/22), responded significantly (p < 0.05) to acute administration of MPD and all 19 responsive
VTA units exhibited a decrease in their neuronal activity following 0.6 mg/kg MPD exposure (Table
5A Sensitization Acute). Most of these sensitized VTA neuronal units, 95% (21/22), exhibited
significant (p < 0.05) changes in their ED10 baseline compared to ED1 baseline, and the majority of
them, 67% (14/21) exhibited attenuation in their ED10 baseline compared to ED1 baseline (Table 5A
Sensitization Saline). At ED10 upon rechallenge with MPD compared to post MPD given at ED1, all
of the VTA units, (22/22) exhibited significant (p < 0.05) changes in their neuronal activity (Table
5A Sensitization Rechallenge) and 64% (14/22) of these responding VTA units exhibited a
significant (p < 0.05) decrease in their activity following 0.6 mg/kg MPD exposure on ED10
compared to 0.6 mg/kg MPD exposure on ED1.
The 3 VTA units that did not respond to 0.6 mg/kg MPD dose on ED1 (Table 5A Sensitization
Acute), exhibited a significant (p < 0.05) change in their ED10 baseline activity as well as to MPD
rechallenge at ED10 after six daily MPD injections and three washout days.
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132
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22
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110
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↑
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Table 5 summarizes the neuronal recording results 0.6 mg/kg. The left, middle, and right columns
summarize the data from all the animals, from those animals expressing behavioral sensitization, and
from those animals expressing behavioral tolerance respectively. The arrows pointing upwards
summarizes the VTA units exhibiting significant increases in neuronal unit activity whereas a
downward arrow implies a decrease in neuronal unit activity and (≠) shows the number of units that
did not respond. The percentages shown next to the numbers summarizes the percentage of units that
responded i.e. total responsiveness. BL- baseline; BL1 – baseline of ED1; BL10 – baseline of ED10;
Rechallenge – MPD exposure at ED10.
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19
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MPD
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0
(0%)
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Table 6 summarizes the electrophysiological results of only the units that responded significantly to
the treatment from Table 5. The units that did not respond to MPD are not represented. Each column
for each dose summarizes the acute and chronic effects of the drug. Acute MPD on ED1 after drug
exposure is compared to ED1 Baseline activity; the ED10 Baseline is compared to ED1 Baseline
activity and the ED10 post MPD is compared to the ED1 post MPD exposure. The same is shown for
each dose broken down into all the recordings (All) and to those animals that exhibited behavioral
sensitization and to those animals that exhibited behavioral tolerance. The arrow pointing upwards
implies a significant increase in neuronal unit activity whereas a downward arrow implies a
significant decrease in neuronal unit activity following MPD exposure. The percentages shown next
to each group is the percentage of units that responded with an increase or decrease in activity (total
responsiveness arbitrarily set as 100%).
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Figure 14 A representative of sequential frequency firing rates of two VTA units following acute 0.6
mg/kg MPD. Both histograms show the neuronal unit activity post saline for 60 minutes, followed by
the neuronal unit activity after MPD on ED1 for the following 60 minutes. The left histogram (14A)
shows the VTA unit exhibited a decrease in firing rate activity to acute MPD administration
compared to the baseline activity, while the right histogram (14B) shows the VTA unit exhibited an
increase in firing rate activity to acute MPD administration compared to the baseline activity.
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3.7.3 Adult VTA Neuronal (2.5 mg/kg)
The neuronal activity of 62 VTA units were recorded after acute and chronic administration
of 2.5 mg/kg MPD; 84% (52/62) of the VTA units responded significantly (p < 0.05) to the initial
exposure of the drug (Table 7B Acute) and of these, the majority 79% (41/52) exhibited a significant
(p < 0.05) increase in firing rate in response to the initial MPD exposure (Table 7B Acute). The
baseline activity of ED10 was altered significantly (p < 0.05) in 95% (59/62) of the VTA units
compared to ED1 baseline (Table 7B Saline; Fig 15) activity as a result of six daily MPD exposures
and three washout days. Of the above VTA units, the majority 53% (31/59), showed a significant (p
< 0.05) decrease in their neuronal activity (Table 7B Saline). At ED10, upon MPD rechallenge
compared to the initial MPD exposure at ED1, 98% (61/62) of the VTA units exhibited significant (p
< 0.05) changes in their neuronal activity (Table 7B Rechallenge), of which the majority 52%
(32/61) of the VTA units responded to the drug by significantly (p < 0.05) attenuating their neuronal
activity (Table 7B Rechallenge). The 9 VTA units that did not respond to MPD exposure on ED1,
exhibited a significant (p < 0.05) change in their ED10 baseline as well as in response to MPD
rechallenge at ED10 after the six daily MPD injections and three washout days (Table7B All).

3.7.4 Adult VTA neuronal based on behavior (2.5 mg/kg)
The neuronal activity of 38 VTA units was recorded from animals that exhibited behavioral
tolerance following acute and chronic 2.5 mg/kg MPD administration. The majority, 90% (34/38),
responded to acute administration of MPD (Table 7B Tolerance Acute), of which 91% (31/34)
exhibited a significant (p < 0.05) increase in neuronal firing rate in response to MPD exposure (Table
8B Tolerance Acute). The ED10 baseline activity compared to ED1 baseline activity was
significantly (p < 0.05) changed for 95% (36/38) of the VTA units (Table 7B Tolerance Saline) and
of these units, 64% (23/36) showed a significant (p< 0.05) increase in their neuronal baseline activity
(Table 8B Tolerance Saline). At ED10 upon rechallenge with MPD compared to post MPD given at
ED1, all of the VTA units (38/38) exhibited significant (p < 0.05) changes in their neuronal activity
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(Table 7B Tolerance Rechallenge) of which 63% (24/38) exhibited a significant (p < 0.05) increase
in their neuronal activity. The 4 units that did not respond to the 2.5 mg/kg MPD dose on ED1 (Table
7B Tolerance Acute), exhibited a significant (p < 0.05) change in their ED10 baseline activity as
well as MPD rechallenge at ED10 after six daily MPD injections and three washout days.
The neuronal activity of 24 VTA units was recorded from animals that exhibited behavioral
sensitization following acute and chronic 2.5 mg/kg MPD administration. The majority, 75%
(18/24), responded to acute administration of MPD (Table 7B Sensitization Acute) and of these 18
responding VTA units, 56% (10/18) exhibited a significant (p < 0.05) increase in neuronal firing rate
in response to MPD (Table 8B Sensitization Acute). The ED10 baseline activity compared to ED1
baseline was changed significantly (p < 0.05) by 96% (23/24) of the VTA units (Table 7B
Sensitization Saline) of which the majority, 78% (18/23), showed a significant (p < 0.05) decrease in
their neuronal activity (Table 8B 2.5 mg/kg Sensitization Saline). At ED10 upon rechallenge with
MPD compared to post MPD given at ED1, the majority of the VTA units, 96% (23/24) exhibited
significant (p < 0.05) changes in their neuronal activity (Table 7B Sensitization Rechallenge), of
which the majority of these responsive units, 78% (18/23) exhibited a significant (p < 0.05) decrease
in their neuronal activity. The 5 units that did not respond to the 2.5 mg/kg MPD dose on ED1 (Table
8B Sensitization Acute), exhibited a significant (p < 0.05) change in their ED10 baseline activity as
well as MPD rechallenge at ED10 after six daily MPD injections and three washout days.
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Table 7 summarizes the neuronal recording results 2.5 mg/kg. The left, middle, and right columns
summarize the data from all the animals, from those animals expressing behavioral sensitization, and
from those animals expressing behavioral tolerance respectively. The arrows pointing upwards
summarizes the VTA units exhibiting significant increases in neuronal unit activity whereas a
downward arrow implies a decrease in neuronal unit activity and (≠) shows the number of units that
did not respond. The percentages shown next to the numbers summarizes the percentage of units that
responded i.e. total responsiveness. BL- baseline; BL1 – baseline of ED1; BL10 – baseline of ED10;
Rechallenge – MPD exposure at ED10.
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Table 8 summarizes the electrophysiological results of only the units that responded significantly to
the treatment from Table 7. The units that did not respond to MPD are not represented. Each column
for each dose summarizes the acute and chronic effects of the drug. Acute MPD on ED1 after drug
exposure is compared to ED1 Baseline activity; the ED10 Baseline is compared to ED1 Baseline
activity and the ED10 post MPD is compared to the ED1 post MPD exposure. The same is shown for
each dose broken down into all the recordings (All) and to those animals that exhibited behavioral
sensitization and to those animals that exhibited behavioral tolerance. The arrow pointing upwards
implies a significant increase in neuronal unit activity whereas a downward arrow implies a
significant decrease in neuronal unit activity following MPD exposure. The percentages shown next
to each group is the percentage of units that responded with an increase or decrease in activity (total
responsiveness arbitrarily set as 100%).
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Figure 15 A representative of sequential frequency firing rates of the baseline of two VTA units at
experimental day 1 (ED1) compared to the baseline at ED10 following six daily 2.5 mg/kg MPD
injections and three washout days. The left histogram (15A) shows the VTA unit that exhibited a
decrease in its baseline firing rate activity at ED10 following six daily 2.5 mg/kg MPD injections and
three washout days compared to the baseline activity on ED1, while the right histogram (15B) shows
the VTA unit exhibited an increase in its baseline firing rate activity at ED10 following six daily 2.5
mg/kg MPD injections and 3 washout days compared to the baseline activity on ED1.
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3.7.5 Adult VTA Neuronal (10.0 mg/kg)
The neuronal activity of 91 VTA units were recorded after acute and chronic administration
of 10.0 mg/kg MPD; 79% (72/91) of the VTA units responded significantly (p < 0.05) to the initial
exposure of the drug (Table 9C Acute) and of these, the majority, 72% (52/72), exhibited a
significant (p < 0.05) increase in firing rate in response to MPD exposure (Table 10C Acute). All of
the units (91/91) exhibited significant (p < 0.05) changes in their ED10 baseline compared to their
ED1 baseline of which, the majority 79% (72/91) showed a significant (p < 0.05) decrease in their
baseline activity (Table 10C Saline). At ED10, upon MPD rechallenge compared to the initial MPD
exposure at ED1, 100% (91/91) of the VTA units exhibited significant (p < 0.05) changes in their
neuronal activity (Table 9C Rechallenge), of which the majority 76% (69/91) of the VTA units
responded to the drug by attenuating their neuronal activity (Table 10C Rechallenge). The 19 VTA
units that did not respond to MPD exposure on ED1, exhibited a significant (p < 0.05) change in
their ED10 baseline as well as in response to MPD rechallenge at ED10 after the six daily MPD
injections and three washout days (Table 9C All).
3.7.6 Adult VTA neuronal based on behavior (10.0 mg/kg)
The neuronal activity of 51 VTA units was recorded from animals that exhibited behavioral
tolerance following acute and chronic 10.0 mg/kg MPD administration. The majority, 69% (35/51)
of them responded to acute administration of MPD (Table 9C Tolerance Acute), of which 91%
(32/35) exhibited a significant (p < 0.05) increase in their neuronal firing rate in response to MPD
exposure (Table 10C Tolerance Acute). All of the units (51/51) exhibited significant (p < 0.05)
changes in their ED10 baseline activity compared to ED1 baseline (Table 9C Tolerance Saline) of
which the majority, 88% (45/51) showed a significant (p < 0.05) decrease in their neuronal activity
(Table 10C Tolerance Saline). At ED10 upon rechallenge with MPD compared to post MPD given at
ED1, all of the VTA units (51/51) exhibited significant (p < 0.05) changes in their neuronal activity
(Table 9C Tolerance Rechallenge) and 84% (43/51) of these exhibited a significant (p < 0.05)
decrease in their neuronal activity. The 16 units that did not respond to the 10.0 mg/kg MPD dose on
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ED1 (Table 9C Tolerance Acute), exhibited a significant (p < 0.05) change in their ED10 baseline
activity compared to their ED1 baseline neuronal firing rate as well as following MPD rechallenge at
ED10 after six daily MPD injections and three washout days, compared to the initial MPD exposure.
The neuronal activity of 40 VTA units was recorded from animals that exhibited behavioral
sensitization following acute and chronic 10.0 mg/kg MPD administration. The majority, 93%
(37/40) responded significantly (p < 0.05) to acute administration of MPD (Table 9C Sensitization
Acute) and of these, 54% (20/37) exhibited a significant (p < 0.05) increase in neuronal firing rate in
response to MPD (Table 10C Sensitization Acute). All of the units (40/40) exhibited significant (p <
0.05) changes in their ED10 baseline firing rate compared to ED1 baseline firing rate (Table 9C
Sensitization Saline), of which the majority 67% (27/40) showed a significant (p < 0.05) decrease in
neuronal activity (Table 10C Sensitization Saline). At ED10 upon rechallenge with MPD compared
to post MPD given at ED1, all of the VTA units (40/40) exhibited significant (p < 0.05) changes in
their neuronal activity (Table 9C Sensitization Rechallenge) of which 65% (26/40) exhibited a
significant (p < 0.05) decrease in their neuronal activity (Table 10C Sensitization Rechallenge). The
3 units that did not respond to the 10.0 mg/kg MPD dose on ED1 (Table 9C Sensitization Acute),
exhibited a significant (p < 0.05) change in their ED10 baseline activity as well as following MPD
rechallenge at ED10 after six daily MPD injections and three washout days.
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Table 9 summarizes the neuronal recording results 0.6 mg/kg. The left, middle, and right columns
summarize the data from all the animals, from those animals expressing behavioral sensitization, and
from those animals expressing behavioral tolerance respectively. The arrows pointing upwards
summarizes the VTA units exhibiting significant increases in neuronal unit activity whereas a
downward arrow implies a decrease in neuronal unit activity and (≠) shows the number of units that
did not respond. The percentages shown next to the numbers summarizes the percentage of units that
responded i.e. total responsiveness. BL- baseline; BL1 – baseline of ED1; BL10 – baseline of ED10;
Rechallenge – MPD exposure at ED10.
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Table 10 summarizes the electrophysiological results of only the units that responded significantly to
the treatment from Table 9. The units that did not respond to MPD are not represented. Each column
for each dose summarizes the acute and chronic effects of the drug. Acute MPD on ED1 after drug
exposure is compared to ED1 Baseline activity; the ED10 Baseline is compared to ED1 Baseline
activity and the ED10 post MPD is compared to the ED1 post MPD exposure. The same is shown for
each dose broken down into all the recordings (All) and to those animals that exhibited behavioral
sensitization and to those animals that exhibited behavioral tolerance. The arrow pointing upwards
implies a significant increase in neuronal unit activity whereas a downward arrow implies a
significant decrease in neuronal unit activity following MPD exposure. The percentages shown next
to each group is the percentage of units that responded with an increase or decrease in activity (total
responsiveness arbitrarily set as 100%).
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Figure 16 A representative of sequential frequency firing rates of two VTA units following acute and
chronic MPD administration. Both histograms show the neuronal unit activity after 60 minutes of
saline i.e. baseline activity, followed by an additional 60 minutes post 10.0 mg/kg MPD on ED1, and
finally by another 60 minutes post 10.0 mg/kg MPD administration on ED10. In 16A, the acute
effect of MPD on ED1 elicits an increase in VTA neuronal unit firing rate compared to the baseline
activity. The effect of MPD rechallenge on ED10, after six daily MPD injections and three washout
day of no drug, results in a lower response to the drug when compared to the effect of the drug on
ED1. This neuronal unit activity was classified as neurophysiological tolerance. In 16B, the acute
effect of 10.0 mg/kg MPD on ED1 results in an increase in neuronal unit activity compared to the
ED1 baseline activity. The effect of MPD administration on ED10 after six daily MPD injections and
three washout days results in a further increase in neuronal unit activity compared to the initial MPD
effects on ED1. This type of response was classified as neurophysiological sensitization.
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3.8 Statistical Comparisons
3.8.1 Adolescent behavioral tolerance compared to sensitized (0.06 mg/kg)
The natural log odds ratio statistical test shows that for 0.6 mg/kg the neuronal recordings
obtained from animals expressing behavioral sensitization were more likely (1.09) to show an
increase in neuronal activity during initial (acute) MPD exposure than those animals expressing
behavioral tolerance. Additionally, for the baseline neuronal activity of ED10 compared to baseline
neuronal activity recorded at ED1 and the neuronal activity recorded on ED10 following rechallenge
with MPD compared to the neuronal activity on ED1 following MPD, the odds ratio revealed that the
behaviorally sensitized animals were more likely (1.21) than the behaviorally tolerant animals to
show an increased neuronal activity on ED10. When comparing the effect of MPD on ED10, both
the behaviorally sensitized and tolerant animals were about as likely to have an increase in activity.
When using a one-way ANOVA comparing the VTA units of those sensitized animals to those
animals who are tolerant, there were no significant differences between the two groups both for ED1
MPD as well as the chronic exposure to MPD on ED10.
3.8.2 Adolescent behavioral tolerance compared to sensitized (2.5 mg/kg)
The natural log odds ratio statistical test shows that for 2.5 mg/kg the neuronal recordings
obtained from animals expressing behavioral sensitization were more likely (1.78, 1.86, 1.42) to
show an increase in neuronal activity for all three comparisons, i.e. the initial (acute) MPD exposure,
the baseline neuronal activity at ED10 compared to baseline activity at ED1 and the neuronal activity
recorded at ED10 following MPD rechallenge compared to the neuronal activity on ED1 in response
to the initial MPD exposure. When using a one-way ANOVA comparing the VTA units of those
sensitized animals to those animals who are tolerant, there were no significant differences between
the two groups both for ED1 MPD as well as the chronic exposure to MPD on ED10.
3.8.3 Adolescent behavioral tolerance compared to sensitized (10.0 mg/kg)
The natural log odds ratio statistical test shows that for 10.0 mg/kg the neuronal recordings
obtained from animals expressing behavioral sensitization were more likely (2.12, 1.72, 1.14) to
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show an increase in neuronal activity for all three comparisons, i.e. the initial (acute) MPD exposure,
the baseline neuronal activity at ED10 compared to baseline activity at ED1 and the neuronal activity
recorded at ED10 following MPD rechallenge compared to the neuronal activity on ED1 in response
to the initial MPD exposure. When using a one-way ANOVA comparing the VTA units of those
sensitized animals to those animals who are tolerant, there were no significant differences between
the two groups both for ED1 MPD as well as the chronic exposure to MPD on ED10.
3.8.4 Adult behavioral tolerant to sensitized (0.06 mg/kg)
The natural log odds ratio statistical test shows that for 0.6 mg/kg the neuronal recordings
obtained from animals expressing behavioral tolerance were more likely (3.82) to show an increase
in neuronal activity during initial (acute) MPD exposure than those animals expressing behavioral
sensitization. In addition, for both the baseline neuronal activity of ED10 compared to baseline
neuronal activity recorded at ED1 and the neuronal activity recorded on ED10 following rechallenge
with MPD administration compared to the neuronal activity on ED1 following MPD exposure, the
odds ratio revealed that both the behaviorally sensitized and behaviorally tolerant animals were about
as likely to show increased neuronal activity. When using a one-way ANOVA comparing the VTA
units of those sensitized animals to those animals who are tolerant, there were no significant
differences between the two groups both for ED1 MPD as well as the chronic exposure to MPD on
ED10 for 0.6 mg/kg MPD.

3.8.5 Adult behavioral tolerant to sensitized (2.5 mg/kg)
The natural log odds ratio statistical test shows that for 2.5 mg/kg the neuronal recordings
obtained from animals expressing behavioral tolerance were more likely (1.99, 1.77 and 1.74) to
show an increase in neuronal activity for all three comparisons, i.e. the initial (acute) MPD exposure,
the baseline neuronal activity at ED10 compared to baseline activity at ED1 and the neuronal activity
recorded at ED10 following MPD rechallenge compared to the neuronal activity on ED1 in response
to the initial MPD exposure. When using a one-way ANOVA comparing the VTA units of those
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sensitized animals to those animals who are tolerant, there were no significant differences between
the two groups both for ED1 2.5 mg/kg MPD, however on ED10 there was a significant (p < 0.05)
difference between the two groups.

3.8.6 Adult behavioral tolerant to sensitized (10.0 mg/kg)
The natural log odds ratio statistical test shows that for 10.0 mg/kg the neuronal recording
obtained from animals expressing behavioral tolerance were more likely (2.07) to show an increase
in neuronal activity during the initial (acute) MPD exposure phase compared to the VTA units
recorded from animals expressing behavioral sensitization to chronic MPD exposure. In addition, the
odds ratio statistical test of the VTA units recorded from animals exhibiting behavioral tolerance
showed that they are more likely (1.23, 1.03) than the behaviorally sensitized animals to exhibit a
decrease in their baseline neuronal activity at ED10 compared to their ED1 baseline activity as well
as for ED10 neuronal activity after MPD rechallenge compared to the neuronal activity on ED1
following MPD administration respectively. When using a one-way ANOVA comparing the VTA
units of those sensitized animals to those animals who are tolerant, there were no significant
differences between the two groups for ED1 10.0 mg/kg MPD, however there was a large significant
difference (p < 0.05) between the two groups on ED10 to chronic 10.0 mg/kg MPD.
3.8.7 Comparison between Adolescent and Adult animals
When we compared the adult and adolescent animals based on their neuronal activity, there
was a significant difference for 0.6 mg/kg MPD on ED1 and ED10 (F: 11.3, P: 0.001; F: 8.9, P:
0.003) for the tolerant animals. In addition, there was a significant difference for 2.5 mg/kg on ED10
only for the sensitized animals (F: 10, P: 0.002). And finally for the dose of 10.0 mg/kg, there was a
significant difference between the adult and adolescent neuronal activity for both ED1 and ED10 and
both the sensitized and tolerant animals (F: 11.3, P: 0.001; F: 64, P: 0.001; F: 6.9; P: 0.01; F: 6.4, P:
0.04).
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4 Discussion
Methylphenidate (MPD) is one of the most prescribed medications for ADHD. However the
its mechanism of action is not fully known and is still under study (Seeman and Madras, 1998;
Solanto 1998; Vanderschuren et al., 2012). MPD has mechanistic similarities to several drugs of
abuse including cocaine, and it also has a chemical structure similar to amphetamine and
methamphetamine (Kallman and Isaac, 1975; Patrick and Markowitz, 1997; Teo et al., 2003). It is
currently hypothesized that ADHD is mostly due to an imbalance in the DA levels in the brain and
drugs like MPD that target the DA systems are effective therapeutic choices for such a disease
(Izenwasser et. al., 1999; Massello and Carpenter, 1999; Patrick and Markowitz, 1997; Volkow and
Swanson, 2008). MPD binds to the dopamine transporter (DAT) which prevents the reuptake of DA
back into the presynaptic terminals from the synaptic cleft causing the extracellular DA to have a
more lasting effect (Volkow et al., 2002). It has been noted that many addictive drugs can elicit
sensitization, tolerance, withdrawal symptoms and dependence, through their action in the CNS
neuronal circuits among them which the VTA plays a critical role (Pierce and Kalivas, 1995; Kalivas
et al. 1993; Nestler, 2008).
In the current study, we recorded VTA neuronal unit activity concomitantly with the
animal’s behavioral locomotor activity both before and after the administration of several acute and
chronic MPD doses. In order to eliminate any environment contributions to the recorded data which
could affect the drug’s effect such as novel condition, all the recordings were done in the animal’s
home cages. Doing so makes sure that any change from baseline activity is due to the drug’s (MPD)
effect and not outside stimulations. The main findings of the current study for the adolescent animals
are that acute MPD elicits a dose response increase in locomotor activity. Similarly, observations
were repeated by Chelaru et al., (2012) in adolescents and by Gaytan et al., (1997; 2000) and Yang et
al., (2003) in adult rats. The same repetitive (chronic) MPD exposure of 0.6, 2.5, or 10.0 mg/kg
elicits either behavioral sensitization in some animals or behavioral tolerance in other animals which
confirms our hypothesis that the same chronic MPD dose will elicit behavioral sensitization in some
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animals and behavioral tolerance in others. This dual observation is the rational as to why we
evaluate the VTA neuronal activity based on the animals’ behavioral response to chronic MPD.
The VTA neurons of adolescent rats responded to acute MPD exposure with a dose response
characteristic, as the MPD dose was increased, more VTA units responded to the drug by changing
their firing rate. The overall baseline activity at ED10 compared to the baseline neuronal activity at
ED1 after six daily MPD exposures and three washout days showed dose response increases in the
total number of units whose baseline was changed; i.e. with increasing the MPD dose from 0.6 to
10.0 mg/kg MPD, more VTA units expressed changes in their ED10 baseline activity compared to
ED1 baseline. This change in ED10 baseline may be expressive of expectation to get the drug again
or withdrawal expression from abrupt stopping of drug exposure (Algahim et al., 2009; Bergheim et
al., 2012; Lee et al., 2011). In response to the chronic administration of MPD at ED10 more units
responded by changing their firing rate compared to the initial MPD exposure. The majority of these
units responded with significant differences in response to MPD rechallenge at ED10 compared to
the responses observed at ED1 after MPD exposure.
Due to the different responses of the VTA neuronal activity following acute compared to
chronic MPD administration, it is possible to classify that there are several types of responses; one
type express neurophysiological sensitization (Fig 16B) and the other type express
neurophysiological tolerance (Fig 16A). Those units that express both an increase in neuronal
activity on ED1 following MPD exposure and a further increase in their neuronal activity on ED10
to MPD rechallenge and those VTA units that exhibit a decrease in neuronal activity to the initial
MPD exposure on ED1 and a further decrease activity on ED10 to MPD rechallenge, are said to
show neurophysiological sensitization. The units that did not respond significantly to MPD on ED1,
but did respond significantly to MPD on ED10 can also be said to exhibit neurophysiological
sensitization. Those VTA units that at ED1 responded to the drug by either increase or attenuation in
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their neuronal activity and at ED10 failed to respond to MPD rechallenge or those VTA units that
show the opposite effects at ED1 compared to ED10 are said to show neurophysiological tolerance.
Since the same dose of MPD either 0.6, 2.5, or 10.0 mg/kg elicits either behavioral
sensitization or tolerance, the VTA neuronal recording from animals expressing behavioral
sensitization to chronic MPD exposure were evaluated separately from the VTA units recorded from
animals expressing behavioral tolerance. It was found that there were significant differences in
response to MPD between these two groups of VTA neuronal populations. The VTA units recorded
from behaviorally sensitized animals were much more likely to show an increase in firing response
upon initial exposure to the drug. Conversely, the VTA units recorded from animals expressing
behavioral tolerance were more likely to exhibit a decrease in the firing rate to acute MPD exposure.
Similar results were observed with the chronic effect of the drug, with the exception of 0.6 mg/kg
group which exhibited more increases in their firing activity in response to the drug from the
behaviorally tolerant animals.
The main findings of the study confirm that the repetitive exposure to each dose of MPD
elicited behavioral sensitization in some animals while eliciting behavioral tolerance in other
animals. This confirmed our study aim that the same repetitive MPD dose can elicit both behavioral
responses. Due to this effect of MPD at each of the doses, we evaluated the neuronal unit activity for
all the animals first with no correlation to their behavioral responses to chronic MPD exposure,
followed by a comparison based on their behavioral response. This was to determine if the VTA
neurons recorded from animals expressing behavioral sensitization responded to acute or chronic
MPD differently than those VTA units recorded from the animals expressing behavioral tolerance.
With this evaluation, we were able to show that in general, the VTA neuronal population recorded
from animals expressing behavioral sensitization did in fact respond differently to MPD compared to
those VTA neuronal populations recorded from animals expressing behavioral tolerance.
Could it be possible that the same dose of MPD can elicit two separate phenomena?
Castellanos et al., (1996) and Arnsten and Dudly (2005) reported such individual differences due to
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varieties in phenotype and also drug metabolic rate between animals following MPD exposure.
Additionally, Volkow and Swanson (2003) who used MRI scans in humans reported different
responses to MPD in normal patients as well as patients who had ADHD which were due to
differences in basal activity of DA in these individuals. In the current study, each shipment contained
about four animals, which could make it possible that each shipment had animals with a different
phenotype and metabolism rate of MPD, which may explain as to why we saw the different
responses observed. This observation stresses the importance to evaluate each animal individually.
Overall, each of the MPD doses (0.6, 2.5 and 10.0 mg/kg) stimulated the majority of the
VTA neuronal units’ activity. The lowest number of VTA units that responded to acute MPD was
observed following 0.6 mg/kg MPD, while 2.5 mg/kg MPD exhibited the highest rate of
responsiveness, followed by 10.0 mg/kg MPD. Following 0.6 mg/kg MPD exposure, the majority of
the VTA units responded to acute MPD by attenuating their firing rate, while following 2.5 and 10.0
mg/kg MPD, the majority of the VTA units responded by increasing their firing rate. Overall, the
ED10 baseline activity when compared to the ED1 baseline showed a dose response increase in the
total number of units that had a change in baseline; i.e. increasing the MPD dose from 0.6 mg/kg to
10.0 mg/kg MPD, the more units that expressed changes in their ED10 baseline compared to ED1
baseline following MPD rechallenge. This change in baseline activity could be the animal expressing
either withdrawal or expectation of MPD (Algahim et al., 2009; Bergheim et al., 2012; Lee et al.,
2011). Upon the rechallenge dose of MPD on ED10 compared to MPD at ED1, the majority of the
VTA units responded to MPD with a decrease in their neuronal activity. For the animals that
expressed behavioral sensitization, there was a “U shape” in the number of units which responded to
the MPD while the opposite was seen from the units recorded from animals expressing behavioral
tolerance which showed a reverse “U shape”. Likewise, the responses to MPD exposure recorded
from animals expressing behavioral sensitization were significantly different when compared to
those VTA units recorded from animals expressing behavioral tolerance.
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There have been several molecular studies (Chao and Nestler, 2004; Kim et al., 2009;
Nestler, 2004) done which have in essence shown similar observations to the current study using
dose response protocols with cocaine, morphine and amphetamine. These studies showed dual
observations which may provide a possible explanation why the same dose of MPD can cause some
VTA units to have excitation and attenuation in other units, as well as behavioral sensitization in
some animals and behavioral tolerance in others. In these studies with cocaine and
methamphetamine, it was noted that some animals expressed the upregulation of the transcription
factor ΔFosB or CREB levels during behavioral sensitization and behavioral tolerance respectively.
The upregulation of CREB in the NAc as a result of chronic drug administration decreased the
rewarding effects of cocaine and morphine (Chao and Nestler, 2004). One of the targets of CREB is
the opioid peptide dynorphin which is expressed in NAc medium spiny neurons (MSN). Dynorphin
release is known to contribute to dysphoria through a negative-feedback loop from the NAc to the
VTA DA neurons which in turn inhibits their activity (Hyman and Malenka, 2001; Spanagel et. al.,
1992). Therefore for the animals that exhibit behavioral tolerance in response to repetitive MPD
exposures, it is possible that the upregulation of CREB is partly responsible for the attenuating
effects of the drug and that the upregulation of CREB induces behavioral tolerance in addition to a
decrease in neuropil density (Chao and Nestler, 2004; Dietz et al., 2009; Kim et al., 2009; Nestler,
2004; 2008). These molecular changings can cause a decrease in the rewarding aspects of MPD and
other psychostimulants (Chao and Nestler, 2004).
Acute exposure to psychostimulants such as MPD and cocaine can induce the upregulation
of ΔFosB (Moratalla et. al., 1996, Chao and Nestler, 2004). This upregulation of ΔFosB following
cocaine exposure results with increased locomotion and is involved in eliciting behavioral
sensitization in mice and is partly responsible for the motivational effects of cocaine (Kelz et. al.,
1999; Chao and Nestler, 2004). Blocking ΔFosB is shown to have opposite effect (Peakman et. al.,
2003). These opposite changes in activity could be attributed to the molecular and morphological
plasticity, which takes place in the MSN density, as well as the upregulation of ΔFosB.
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Consequently, animals which exhibited higher MSN density or expressed an upregulation of ΔFosB
following chronic MPD exposure would show a further increase in activity to rechallenge MPD
respectively. As a result, it is possible that the animals that expressed behavioral sensitization or
behavioral tolerance to MPD in the current study could be experiencing these dual molecular
transcription factor changes in the CNS circuitry; and can provide further explanation to the present
observation why the same dose of MPD can cause both behavioral sensitization and tolerance or
increase activity in some VTA units and decreases in their activity in response to MPD exposure in
other VTA units.
VTA neurons contain both D1 and D2 DA receptors, which are affected by drugs like MPD
and the glutamatergic afferent inputs from the PFC, in addition to other neurons in the VTA. DA D1
receptors have an excitatory effect when activated, while the DA D2 receptors have an inhibitory
effect on other cells when they are activated. It is possible that the VTA neurons which exhibit
mainly a decrease in their activity are being recorded from an area of the VTA that contains mostly
DA D2 receptors whose activation gives the decrease in activity. Conversely, the cells which
exhibited mainly an increase in activity could be recorded from an area of the VTA containing
mostly DA D1 neurons. Furthermore to these units, the afferent input of glutamatergic neurons from
the PFC to DA neurons in the VTA can be affected by MPD which in turn affect how they fire to the
VTA and could also be partially responsible to the different responses to MPD.
It was reported that low doses of MPD mainly affect the DA D2 autoreceptors in the VTA
which leads to the attenuation of DA release in response to a stimulus such as MPD (Seeman and
Madras, 1998, 2002). These auto-receptors counter regulate the extracellular DA released from the
same cell and are likely the reason that 0.6 mg/kg MPD elicited a decrease in the locomotor activity
of some animals. The exposure to the higher doses of 2.5 mg/kg and 10.0 mg/kg MPD overcome the
inhibitory effects of the presynaptic auto-receptors with increased DA levels in the cleft and post
synaptic activation which causes amplification of the DA signals as observed in this study (Volkow
et. al., 2005). For the animals which exhibited behavioral sensitization, the majority of their neuronal
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responses to MPD elicited a decrease in activity on ED10 regardless of an increase or decrease in
activity on ED1 following MPD administration. For the animals that expressed behavioral tolerance,
different patterns were observed.
It is believed that MPD works in a biphasic action, which includes a “spontaneous” phasic
and tonic release of DA. The phasic release of DA from synaptic terminals is large but brief, and
activates the postsynaptic DA receptors evoking DA dependent behavioral responses (Seeman and
Madras, 1998, 2002). The other mode of action, tonic DA release, from the VTA is regulated by the
presynaptic NMDA receptors controlled by glutamatergic afferents from the PFC (Grace, 1991).
During normal nerve impulses the basal levels of DA rise about 60-fold and quickly diminish back to
normal levels. With the low doses of MPD (0.6 mg/kg), the resting level of DA rises about 6-fold
and is thought to act mostly on DA D2 autoreceptors which reduce the impulses which triggered the
DA release. At higher doses of MPD exposure (2.5 and 10.0 mg/kg), both the resting DA levels and
the triggered DA output are increased significantly causing the wide spread stimulation of
postsynaptic DA receptors which cause strong stimulation (Seeman and Madras, 1998, 2002) and
can help to explain why low doses of MPD can cause lower levels of activation and the higher doses
of 2.5 mg/kg and 10.0 mg/kg MPD provide increased levels of activity upon acute administration of
the drug.
In several studies, it has been reported that psychostimulants such as MPD can elicit
increases in neuropil (the density and the dendritic branching of the MSN) in the NAc and PFC,
while at the same time in other animals, elicits a decrease in the neuropil levels following the same
dose of stimulant (Kim et al., 2009; Nestler, 2008; Robinson and Kolb, 1997; 1999). We suggest that
the animals which expressed the increases in their neuropil as a result of chronic psychostimulant
exposure would respond to rechallenge drug administration by increasing their firing rate and those
animals which elicited decreases in their neuropil would respond to MPD by decreasing their firing
rate.
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Based on the responses to acute and chronic MPD, we have classified two types of neuronal
activity. The first type of neuronal unit activity expresses neurophysiological sensitization and the
second type expresses neurophysiological tolerance. The units that express both an increase in
neuronal activity on ED1 after MPD administration and yet a further increase in their neuronal
activity on ED10 following the MPD rechallenge dose, as well as the VTA units that exhibit a
decrease in their neuronal activity to MPD on ED1 and a further decrease activity on ED10 to MPD
rechallenge, exhibit neurophysiological sensitization. Some units did not respond significantly to
MPD administration on ED1, but did respond significantly on ED10 following MPD can also be said
to exhibit this neurophysiological sensitization. Those VTA units who responded to the drug by
either increase or attenuation in their neuronal activity at ED1 and failed to respond to MPD
rechallenge on ED10, as well as those VTA units that show the opposite effects at ED1 compared to
ED10 are said to show neurophysiological tolerance.
When we applied the one way ANOVA and odds ratio tests comparing the effect of MPD on
the VTA neuronal units recorded from animals expressing behaviorally sensitization to those units
recorded from behaviorally tolerant animals for each dose, we found that the neuronal population
recorded in the VTA from animals that express behavioral sensitization to repetitive MPD exposure
did in fact respond differently to MPD compared to those VTA units recorded in animals expressing
behavioral tolerance. These two tests show the importance of evaluating the neuronal firing rates
following psychostimulant exposure based off of the animal’s behavior in order to find any
correlations between drug dose and firing rates with behavioral activity. We observed differences
between the adolescent and adult animals in how they responded to MPD. In general, both groups
showed dose response effects to the drug. The adolescents seemed to have higher activation to low
dose MPD, while the adults had more activity following higher doses of MPD. This helps to show
that there are inherent differences between the two age groups in how they respond to MPD and that
the drug affects younger individuals differently than older individuals. This could be due to the
adolescent brains continuing to go through synaptic pruning and shaping of the adult brain as well as
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different molecular, morphological, and metabolic differences that come with age. We highlighted
the importance of looking at both groups of animals as well as shed light on the differences between
them. It will be important in future experiments to further the knowledge of MPD’s effects on both
groups and why the changes in activity
In conclusion, the current study showed that the VTA neuronal population activity recorded
from animals expressing behavioral sensitization to chronic MPD, responded to MPD exposure
differently from those VTA units recorded in animals expressing behavioral tolerance and that the
effect of MPD on VTA neurons is different from other psychostimulants, i.e. MPD has its own
unique effect that needs to be elucidated. We were able to show differences between the adolescent
and adult animals which show that MPD can have differing effects on each group. This study can
help to explore those differences and shows the importance of looking at both adult and adolescent
studies for drugs such as MPD due to their wide usage in society and the potential risks they pose.
Additionally, this study shows the importance of looking at individual responses to the acute effect
of the drug and the baseline levels of individuals as a way to gauge how they will react to
psychostimulants such as MPD. Moreover, the observation that the same repetitive MPD dose
elicited behavioral sensitization in some animals while causing behavioral tolerance in others is
essential information that the professional practitioners and the MPD users need to consider.
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